Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
ADHESIN TIP MULTIEPITOPE FUSION ANTIGEN PLATFORM AND VACCINES
AND THEIR USE IN THE TREATMENT OF ENTEROTOXIGENIC DIARRHEA
BACKGROUND OF THE INVENTION
[0001] Diarrhea continues to be a leading cause of death in children
younger than 5 years
who living in developing countries. Enterotoxigenic Escherichia coli (ETEC) is
a leading
bacterial cause of children's diarrhea and travelers' diarrhea. ETEC bacteria
attaching host
receptors at epithelial cells and colonizing in the small intestine initiate
ETEC-associated
diarrheal disease. Therefore, preventing ETEC attachment has been considered
the first line of
defense against ETEC diarrhea. However, ETEC strains produce over 23
immunologically
heterogeneous adhesins, which makes developing vaccines that broadly protect
against ETEC
bacterial attachment challenging. Accordingly, what is needed is a composition
that provides a
protective effect against ETEC. What is further needed is a composition that
induces antibody
responses to multiple ETEC adhesins. What is also needed is a composition that
impairs,
reduces, or even prevents ETEC attachment.
SUMMARY OF THE INVENTION
[0002] The present disclosure overcomes the problems inherent in the prior
art by applying
a MEFA (multiepitope fusion antigen) approach to integrate epitopes from
adhesin tips or
adhesive subunits of CFA/I, CS1, C52, C53, C54, C55, C56, C521, EtpA, or other
ETEC
adhesins and to construct representative adhesin tip MEFA peptides (tip MEFA-
I, tip MEFA-II),
or epitopes from the major structural subunits of C57, CS12, CS14, CS17, CS19,
C521, EtpA,
and EaeH adhesins for a major subunit CFA MEFA (CFA MEFA-II). The antigenicity
of each
tip MEFA or the CFA MEFA was then examined in mouse immunization, and assessed
for
potential application for ETEC vaccine development. Data showed mice
intraperitoneally
1
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
immunized with ETEC adhesin tip MEFA-I developed IgG antibody responses to all
nine ETEC
adhesins (CFA/I, CS1-CS6, CS21, EtpA). Moreover, ETEC and E. coli bacteria
expressing
these nine adhesins, after incubation with serum of the immunized mice, had
significant
reduction of attachment to Caco-2 cells. Similarly, mice immunized with ETEC
adhesin tip
MEFA-II developed IgG antibodies against attachment of CS12, CS14, CS17, C519
and EaeH,
and mice immunized with major subunit CFA MEFA-II developed IgG antibodies
against C57,
CS12, CS14, CS17, CS19, C521, EtpA and EaeH adhesins. These results indicated
that anti-
adhesin antibodies induced by an adhesin tip MEFA or a CFA major subunit MEFA
blocked
adherence of the most important ETEC adhesins, suggesting that multivalent tip
MEFA-I, tip
MEFA-II, and the CFA MEFA-II can be useful for developing a broadly protective
anti-adhesin
vaccine against ETEC diarrhea.
[0003] Thus, the present disclosure utilizes an MEFA (multiepitope fusion
antigen)
approach to integrate epitopes from adhesin tips or adhesive subunits of
CFA/I, CS1, C52, C53,
C54, C55, C56, C521 C57, CS12, CS14, CS17, CS19, EaeH, and EtpA adhesins to
construct at
least one adhesin tip MEFA peptide(s). Data showed mice intraperitoneally or
subcutaneously
immunized with an adhesin tip MEFA developed IgG antibody responses to all
representing
ETEC adhesins. Moreover, after incubation with serum of the immunized mice,
ETEC and E.
coli bacteria expressing these adhesins had significant reduction of
attachment to Caco-2 cells.
This MEFA approach was also used to integrate epitopes from the major
structural subunits of
C57, CS12, CS14, CS17, CS19, C521, EtpA and EaeH adhesins into a CFA major
structural
subunit MEFA (CFA MEFA-II). This CFA MEFA-II was then examined for
immunogenicity in
mouse immunization studies. Data showed that immunized mice developed strong
IgG
antibodies to each of eight target adhesins; moreover, the induced antibodies
significantly
2
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
reduced adherence of ETEC strains expressing each of these eight adhesins to
Caco-2 cells.
These results indicated that anti-adhesin antibodies induced by each adhesin
tip MEFA or the
CFA MEFA-II blocked adherence of the most important ETEC adhesins, suggesting
the
multivalent tip MEFA (tip MEFA-I, tip MEFA-II) or the major structural subunit
MEFA (CFA
MEFA-II) can be useful for developing a broadly protective anti-adhesin
vaccine against ETEC
diarrhea. "MEFA" refers to and encompasses both adhesin tip and major
structural subunit
MEFA.
[0004] The present disclosure provides for at least three, preferably,
four, more preferably
five, still more preferably six, even more preferably seven, still more
preferably eight or more
multi epitope fusion antigens (MEFA) comprising a nucleotide fragment encoding
a polypeptide
backbone from a colonization factor antigen (CFA) having epitopes from adhesin
tips, adhesive
subunits or major structural subunits of Enterotoxigenic Escherichia coli
(ETEC) incorporated
therein. In one embodiment, the epitopes from adhesin tips or adhesive
subunits of ETEC are
preferably selected from the group consisting of CFA/I, CS1, CS2, CS3, CS4,
CS5, CS6, CS12,
CS14, CS17, CS19, C521, EtpA, EaeH, and any combination thereof. In one
embodiment, there
may be a single or multiple copies of each epitope present in the MEFA from
the structural
major subunits of C57, CS12, CS14, CS17, CS19, C521, EtpA and EaeH adhesins
present in a
MEFA.
[0005] In a further aspect, the present disclosure provides for an adhesin
tip MEFA
comprising nucleotides encoding a polypeptide backbone from a colonization
factor antigen
(CFA) having epitopes from adhesin tips or adhesive subunits of ETEC
incorporated therein,
wherein the backbone to which the epitopes are attached is preferably selected
from, but not
limited to, CfaE, CS14, and C521. The present disclosure also provides for an
adhesin major
3
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
structural subunit CFA MEFA-II composing nucleotides encoding a polypeptide
backbone from
a colonization factor antigen (CFA) having epitopes from adhesin major
structural subunits of
CS7, CS12, CS14, CS17, CS19, CS21, EtpA, and EaeH ETEC adhesins incorporated
therein.
[0006] The adhesin tip or major subunit MEFAs disclosed herein may further
comprise
additional elements, where such elements are selected from the group
consisting of, but not
limited to, heat liable toxin (LT), heat stable toxin (STa), an epitope from
adhesin of
enteroaggregative E.coli (EAEC), epitopes of cholera, epitopes of rotavirus,
and any
combination thereof. There may be one or more copies of LT and/or STa in any
given adhesin
tip MEFA of the present disclosure.
[0007] In one aspect, the present disclosure provides for a nucleic acid
molecule that
encodes for the polypeptide molecules described herein.
[0008] Further, the present disclosure provides for an expression vector
comprising a
nucleic acid molecule encoding the polypeptide molecules described herein.
[0009] In another aspect, the present disclosure provides for an
immunogenic composition
or vaccine composition comprising the polypeptide molecules described herein
and a
pharmaceutically acceptable vehicle, adjuvant, carrier and any combination
thereof.
[0010] In a further aspect, a method of inducing an immune response against
ETEC is
provided. Preferably, the steps of the method include, but are not limited to,
administration of
one or more of the polypeptide(s) described herein to a human or animal in
need thereof.
[0011] In yet another aspect, a method of reducing the severity or
incidence of the clinical
signs of ETEC infection is also provided in the present disclosure. The method
of reducing the
clinical signs of ETEC infection includes, but is not limited to, the step of
administration of one
or more the polypeptide(s) and/or adhesin tip MEFA(s) and/or CFA major subunit
MEFA(s)
4
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
disclosed herein to a human or animal in need thereof. The reduction in
severity or incidence is
in comparison to an animal or human, or group of animals or humans, that has
not received an
administration of one or more polypeptide(s) of the present disclosure.
[0012] Another aspect of the present disclosure includes a method of
treating or reducing
the incidence or severity of diarrhea. The method preferably comprises the
steps of
administration of one or more of the polypeptide(s) and/or adhesin tip MEFA(s)
and/or CFA
major subunit MEFA(s), as described herein, to a human or animal in need
thereof. The treating
or reducing the incidence or severity of diarrhea is in comparison to an
animal or human, or
group of animals or humans, that has not received an administration of one or
more
polypeptide(s) and/or adhesin tip MEFA(s) and/or CFA major subunit MEFA(s) of
the present
disclosure.
[0013] A method of reducing adherence of the ETEC bacteria to the intestine
is also
provided. The method preferably comprises the steps of administration of one
or more of the
polypeptide(s) and/or adhesion tip MEFA(s) and/or CFA major subunit MEFA(s) to
a human or
animal in need thereof. The adherence is in comparison to an animal or human,
or group of
animals or humans, that has not received an administration of one or more
polypeptide(s) and/or
adhesin tip MEFA(s) and/or CFA major subunit MEFA(s) of the present
disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The drawings described herein are for illustration purposes only and
are not
intended to limit the scope of the present teachings in any way.
[0015] Figure 1 is a schematic illustration of the constructed ETEC adhesin
tip MEFA-I
protein. Amino acid sequences of the epitopes from each adhesin tip or
adhesive subunit are
shown in the top panel. The bottom left panel shows results of Western blot
with mouse anti-
CFA/I antiserum, 9450 was the adhesin tip MEFA protein (25 and 30 1), and (-)
was the total
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
proteins from BL21 E. coli. The bottom right panel showed Coomassie blue
staining of refolded
solubilized adhesin tip MEFA proteins (lane 1: protein marker; lane 2: 25 1
tip MEFA protein;
lane 3: 30 1 tip MEFA protein);
[0016] Fig. 2 is a plot of serum anti-CfaE (CFA/I), -CooD (CS1), -CotD
(CS2), -CstH
(CS3), -CsaE (C54), -CsfD (C55), -CssB (C56), anti-LngA (C521) and anti-EtpA
(EtpA) IgG
antibody titers (logio) from mice immunized with tip MEFA-I. Solid circles (=)
are titers of
mice intraperitoneally immunized with the adhesin tip MEFA-I protein. Each
circle represented
the IgG titer from an individual mouse. Bars indicated the mean titers of the
group specific to
each adhesin;
[0017] Fig. 3 is an illustration of a host cell and bacterial cell showing
adhesin interaction;
[0018] Fig. 4 is an illustration of the genetic structure of adhesin MEFA-I
with a CS14
adhesin tip subunit CsuD as the backbone, with two CsuD epitopes retained,
where 4 epitopes
were substituted with epitopes from tip subunits of C512 (CswF), C517 (CsbD),
C519 (CsdD)
and EaeH adhesins;
[0019] Fig. 5 is a plot of serum IgG antibody titers (logio) for anti-CS12,
anti-CS14, anti
CS17, anti-CS19, and anti-EaeH IgG antibodies from mice subcutaneously
immunized with
adhesin tip MEFA-II protein, where each dot represented an IgG titer from an
individual mouse
and bars indicated mean titers;
[0020] Fig. 6 is an illustration of the genetic structure of major subunit
CFA MEFA-II with
a C521 major subunit LngA as the backbone, with a LngA surface-exposed and
epitopes from
the major subunits of C57, CS12, CS14, CS17, CS19, EtpA and EaeH adhesins;
[0021] Fig. 7 is a plot of serum IgG antibody titers (logio) for anti-057,
anti-CS12, anti-
CS14, anti CS17, anti-CS19, anti-0521, anti-EaeH and anti-EtpA IgG antibodies
from mice
6
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
subcutaneously immunized with major subunit CFA MEFA-II, where each dot
represented an
IgG titer from an individual mouse and bars indicated mean titers; and
[0022] Fig. 8 is an illustration of a MEFA of the present disclosure
illustrating the epitopes
being incorporated into the backbone.
DETAILED DESCRIPTION
[0023] The present disclosure provides for a multi epitope fusion antigen
(MEFA)
comprising a polypeptide including epitopes from adhesin tips or adhesive
subunits of
Enterotoxigenic Escherichia coli (ETEC). In one embodiment, the epitopes from
adhesin tips or
adhesive subunits of ETEC are preferably selected from the group consisting of
the adhesin tip
or adhesive subunit of CFA/I, CS1, C52, C53, C54, C55, C56, C57, C512, C514,
C517, C519,
C521, EtpA, EaeH and combinations thereof. In one embodiment, the polypeptide
comprises at
least 2 epitopes, at least 3 epitopes, at least 4 epitopes, at least 5
epitopes, at least 6 epitopes, at
least 7 epitopes, at least 8 epitopes, at least 9 epitopes, at least 10
epitopes, at least 11 epitopes, at
least 12 epitopes, at least 13 epitopes, at least 14 epitopes, and at least 15
epitopes.
[0024] The CS1 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by a nucleotide sequence that is
associated with
the CS1 genome from ETEC, including any fragment or portion thereof. The CS1
genome is
preferably the nucleotide sequence encoding SEQ ID No.47 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
47. In one embodiment, the CS1 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 3 and SEQ ID No. 4. One such preferred nucleotide
sequence is SEQ
ID No. 55. In an alternate embodiment, the CS1 epitope nucleotide sequence is
selected from a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
7
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
homology with a sequence generated from the primers selected from SEQ ID No. 3
and SEQ ID
No. 4. Preferably, the CS1 epitope is an adhesin tip or adhesive subunit. In
one embodiment,
the epitope from CS1 is selected from the nucleotide sequence encoding SEQ ID
No. 37 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 37.
[0025] The C52 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C52 genome from ETEC, including any fragment or portion thereof. The C52
genome is
preferably the nucleotide sequence encoding SEQ ID No.48 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
48. In one embodiment, the C52 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 5 and SEQ ID No. 6. One such preferred nucleotide
sequence is SEQ
ID No. 56. In an alternate embodiment, the C52 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with a
sequence generated from the primers selected from SEQ ID No. 5 and SEQ ID No.
6.
Preferably, the C52 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the epitope
from C52 is selected from the nucleotide sequence encoding SEQ ID No. 42 and a
sequence that
has at least 80%, at least 85%, at least 90%, or at least 95% sequence
identity or homology with
the nucleotide sequence encoding SEQ ID No. 42.
[0026] The C53 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C53 genome from ETEC, including any fragment or portion thereof. The C53
genome is
preferably the nucleotide sequence encoding SEQ ID No.49 or any sequence
having at least
8
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
49. In one embodiment, the C53 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 7 and SEQ ID No. 8. One such preferred nucleotide
sequence is SEQ
ID No. 57. In an alternate embodiment, the C53 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with a
sequence generated from the primers selected from SEQ ID No. 7 and SEQ ID No.
8.
Preferably, the C53 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from C53 is selected from the nucleotide sequence encoding SEQ ID No.
36 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 36.
[0027] The C54 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C54 genome from ETEC, including any fragment or portion thereof. The C54
genome is
preferably the nucleotide sequence encoding SEQ ID No.50 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
50. In one embodiment, the C54 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 9 and SEQ ID No. 10. One such preferred nucleotide
sequence is
SEQ ID No. 58. In an alternate embodiment, the C54 epitope is selected from a
sequence that
has at least 80%, at least 85%, at least 90%, or at least 95% sequence
identity or homology with
a sequence generated from the primers selected from SEQ ID No. 9 and SEQ ID
No. 10.
Preferably, the C54 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from C54 is selected from the nucleotide sequence encoding SEQ ID No.
41 and a
9
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 41.
[0028] The C55 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C55 genome from ETEC, including any fragment or portion thereof. The C55
genome is
preferably the nucleotide sequence encoding SEQ ID No.51 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
51. In one embodiment, the C55 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 11 and SEQ ID No. 12. One such preferred nucleotide
sequence is
SEQ ID No. 59. In an alternate embodiment, the C55 epitope is selected from a
sequence that
has at least 80%, at least 85%, at least 90%, or at least 95% sequence
identity or homology with
a sequence generated from the primers selected from SEQ ID No. 11 and SEQ ID
No. 12.
Preferably, the C55 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from C55 is selected from the nucleotide sequence encoding SEQ ID No.
35 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 35.
[0029] The C56 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C56 genome from ETEC, including any fragment or portion thereof. The C56
genome is
preferably the nucleotide sequence encoding SEQ ID No.52 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
52. In one embodiment, the C56 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 15 and SEQ ID No. 16. One such preferred nucleotide
sequence is
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
SEQ ID No. 60 or any sequence having at least 80%, at least 85%, at least 90%,
or at least 95%
sequence identity or homology with SEQ ID No. 60.
[0030] In an alternate embodiment, the CS6 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with a
sequence generated from the primers selected from SEQ ID No. 13 and SEQ ID No.
14.
Preferably, the C56 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from C56 is selected from the nucleotide sequence encoding SEQ ID No.
38 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 38.
[0031] The C521 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C521 genome from ETEC, including any fragment or portion thereof. The C521
genome is
preferably the nucleotide sequence encoding SEQ ID No.53 or any sequence
having at least
80%, at least 85%, at least 90%, or at least 95% sequence identity or homology
with SEQ ID No.
53. In one embodiment, the C521 epitope nucleotide sequence is generated from
the primers
selected from SEQ ID No. 15 and SEQ ID No. 16. One such preferred nucleotide
sequence is
SEQ ID No. 61. In an alternate embodiment, the C521 epitope is selected from a
sequence that
has at least 80%, at least 85%, at least 90%, or at least 95% sequence
identity or homology with
a sequence generated from the primers selected from SEQ ID No. 15 and SEQ ID
No. 16.
Preferably, the C521 epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from C521 is selected from the nucleotide sequence encoding SEQ ID No.
39 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 39.
11
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0032] The EtpA epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the EtpA genome from ETEC, including any fragment or portion thereof. The EtpA
genome is
preferably the nucleotide sequence encoding SEQ ID No.2 or any sequence having
at least 80%,
at least 85%, at least 90%, or at least 95% sequence identity or homology with
SEQ ID No. 2. In
one embodiment, the EtpA epitope nucleotide sequence is generated from the
primers selected
from SEQ ID No. 17 and SEQ ID No. 34. One such preferred nucleotide sequence
is SEQ ID
No. 62. In an alternate embodiment, the EtpA epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with a
sequence generated from the primers selected from SEQ ID No. 17 and SEQ ID No.
34.
Preferably, the EtpA epitope is an adhesin tip or adhesive subunit. In one
embodiment, the
epitope from EtpA is selected from the nucleotide sequence encoding SEQ ID No.
40 and a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with the nucleotide sequence encoding SEQ ID No. 40.
[0033] The C57 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the C57 genome from ETEC, including any fragment or portion thereof. In one
embodiment, the
C57 epitope is selected from the nucleic acid sequence encoding SEQ ID No. 22
and/or the
nucleic acid sequence encoding SEQ ID No. 29 and/or the nucleic acid sequence
encoding SEQ
Id NO. 68. In an alternate embodiment, the C57 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with either
the nucleic acid sequence encoding SEQ ID No. 22 and/or the nucleic acid
sequence encoding
SEQ ID No. 29 and/or the nucleic acid sequence encoding SEQ Id NO. 68. In
another alternate
12
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
embodiment, the CS7 epitope is selected from a sequence that has at least 80%,
at least 85%, at
least 90%, or at least 95% sequence identity or homology with SEQ ID No. 22
and/or SEQ ID
No. 29 and/or the nucleic acid sequence encoding SEQ Id NO. 68. Preferably,
the C57 epitope
is an adhesin tip or adhesive subunit.
[0034] The CS12 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the CS12 genome from ETEC, including any fragment or portion thereof. In one
embodiment,
the CS12 epitope is selected from the nucleic acid sequence encoding SEQ ID
No. 24 and/or the
nucleic acid sequence encoding SEQ ID No. 30 and/or the nucleic acid sequence
encoding SEQ
Id NO. 69. In an alternate embodiment, the CS12 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with either
the nucleic acid sequence encoding SEQ ID No. 24 or the nucleic acid sequence
encoding SEQ
ID No. 30 and/or the nucleic acid sequence encoding SEQ Id NO. 69. In another
alternate
embodiment, the CS12 epitope is selected from a sequence that has at least
80%, at least 85%, at
least 90%, or at least 95% sequence identity or homology with SEQ ID No. 24
and/or SEQ ID
No. 30 and/or the nucleic acid sequence encoding SEQ Id NO. 69. Preferably,
the CS12 epitope
is an adhesin tip or adhesive subunit.
[0035] The CS14 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the CS14 genome from ETEC, including any fragment or portion thereof. In one
embodiment,
the CS14 epitope is selected from the nucleic acid sequence encoding SEQ ID
No. 21, and/or the
nucleic acid sequence encoding SEQ ID No. 23, and/or the nucleic acid sequence
encoding SEQ
ID No. 26 and/or the nucleic acid sequence encoding SEQ Id NO. 70. In an
alternate
13
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
embodiment, the CS14 epitope is selected from a sequence that has at least
80%, at least 85%, at
least 90%, or at least 95% sequence identity or homology with one or more of
the nucleic acid
sequence encoding SEQ ID No. 21, the nucleic acid sequence encoding SEQ ID No.
23, and the
nucleic acid sequence encoding SEQ ID No. 26 and/or the nucleic acid sequence
encoding SEQ
Id NO. 70. In another alternate embodiment, the CS14 epitope is selected from
a sequence that
has at least 80%, at least 85%, at least 90%, or at least 95% sequence
identity or homology with
SEQ ID No. 21, SEQ ID No. 23, and/or SEQ ID No. 26 and/or the nucleic acid
sequence
encoding SEQ Id NO. 70. Preferably, the CS14 epitope is an adhesin tip or
adhesive subunit.
[0036] The CS17 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the CS17 genome from ETEC, including any fragment or portion thereof. In one
embodiment,
the CS17 epitope is selected from the nucleotide sequence encoding SEQ ID No.
25 and/or the
nucleotide sequence encoding SEQ ID No. 31 and/or the nucleic acid sequence
encoding SEQ
ID NO. 71. In an alternate embodiment, the CS17 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with either
the nucleotide sequence encoding SEQ ID No. 25 or the nucleotide sequence
encoding SEQ ID
No. 31 and/or the nucleic acid sequence encoding SEQ ID NO. 71. In another
alternate
embodiment, the CS17 epitope is selected from a sequence that has at least
80%, at least 85%, at
least 90%, or at least 95% sequence identity or homology with SEQ ID No. 25
and/or SEQ ID
No. 31 and/or the nucleic acid sequence encoding SEQ ID NO. 71. Preferably,
the CS17 epitope
is an adhesin tip or adhesive subunit.
[0037] The CS19 epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
14
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
the CS19 genome from ETEC, including any fragment or portion thereof. In one
embodiment,
the CS19 epitope is selected from the nucleotide sequence encoding SEQ ID No.
27 and/or the
nucleotide sequence encoding SEQ ID No. 32 and/or the nucleic acid sequence
encoding SEQ
ID NO. 72. In an alternate embodiment, the CS19 epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with either
the nucleotide sequence encoding SEQ ID No. 27 or the nucleotide sequence
encoding SEQ ID
No. 32 and/or the nucleic acid sequence encoding SEQ ID NO. 72. In another
alternate
embodiment, the CS19 epitope is selected from SEQ ID No. 27 and/or SEQ ID No.
32 and/or the
nucleic acid sequence encoding SEQ ID NO. 72. Preferably, the CS19 epitope is
an adhesin tip
or adhesive subunit.
[0038]
The EaeH epitope for purposes of the present disclosure includes any
nucleotide
sequence or the amino acid sequence encoded by the nucleotide sequence that is
associated with
the EaeH genome from ETEC, including any fragment or portion thereof. In one
embodiment,
the EaeH epitope is selected from the nucleotide sequence encoding SEQ ID No.
28 and/or the
nucleotide sequence encoding SEQ ID No. 33 and/or the nucleic acid sequence
encoding SEQ
ID NO. 73. In an alternate embodiment, the EaeH epitope is selected from a
sequence that has at
least 80%, at least 85%, at least 90%, or at least 95% sequence identity or
homology with either
the nucleotide sequence encoding SEQ ID No. 28 and/or the nucleotide sequence
encoding SEQ
ID No. 33 and/or the nucleic acid sequence encoding SEQ ID NO. 73. In an
alternate
embodiment, the EaeH epitope is selected from a sequence that has at least
80%, at least 85%, at
least 90%, or at least 95% sequence identity or homology with SEQ ID No. 28
and/or SEQ ID
No. 33 and/or the nucleic acid sequence encoding SEQ ID NO. 73. Preferably,
the EaeH
epitope is an adhesin tip or adhesive subunit.
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0039] In a further aspect, the present disclosure provides for an adhesin
tip MEFA
comprising a polypeptide encoding epitopes from adhesion tips or adhesive
subunits of ETEC,
wherein the polypeptide encodes a colonization factor antigen (CFA) backbone
to which the
epitopes are attached. The backbone is preferably selected from, but not
limited to, CfaE, CfaA,
CfaB, CfaC, CS14, CS7, CS12, CS17, CS19, CS21, and combinations thereof. In a
particularly
preferred embodiment, the backbone is selected from CfaE, CS14, and C521.
[0040] The CfaE backbone for purposes of the present disclosure includes
any nucleotide
sequence or amino acid sequence or the product produced by the nucleotide
sequence associated
with the CfaE genome from ETEC, including any fragment or portion thereof. In
one
embodiment, the CfaE backbone is selected from the sequence generated by the
primers SEQ ID
No. 18 and SEQ ID No. 19. In an alternate embodiment, the CfaE backbone is
selected from a
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with a sequence generated by the primers SEQ ID No. 18 and SEQ ID No.
19. In
some preferred forms, the CfaE backbone has at least 80%, at least 85%, at
least 90%, or at least
95% sequence identity or homology with SEQ ID No. 46. In another embodiment,
the amino
acid sequence of the CfaE backbone is SEQ ID No. 46. In a further embodiment,
the CfaE
backbone retains one or more epitopes of CfaE. Such CfaE epitopes are
preferably selected from
the nucleotide sequence encoding SEQ ID No. 43, the nucleotide sequence
encoding SEQ ID
No. 44, the nucleotide sequence encoding SEQ ID No. 45, and sequences having
at least 80%, at
least 85%, at least 90%, or at least 95% sequence identity or homology with
the nucleotide
sequence encoding SEQ ID No. 43, SEQ ID NO. 44, or SEQ ID No. 45.
[0041] In a further aspect, the present disclosure provides for an adhesin
major subunit
MEFA of C521 comprising a polypeptide encoding epitopes from adhesion tips or
adhesive
16
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
subunits of CS7, CS12, CS14, CS17, CS19, EtpA, and EaeH, wherein the
polypeptide encodes a
colonization factor antigen (CFA) backbone to which the epitopes are attached.
In a preferred
aspect, the C521 backbone retains two epitopes.
[0042] The CS14 backbone for purposes of the present disclosure includes
any nucleotide
sequence or amino acid sequence or the product produced by the nucleotide
sequence associated
with the C514 genome from ETEC, including any fragment or portion thereof. In
one
embodiment, the CS14 backbone is selected from the nucleotide sequence
encoding SEQ ID No.
21 and a sequence that has at least 80%, at least 85%, at least 90%, or at
least 95% sequence
identity or homology with the nucleotide sequence encoding SEQ ID No.21. In an
alternative
embodiment, the CS14 backbone is selected from the a sequence that has at
least 80%, at least
85%, at least 90%, or at least 95% sequence identity or homology with SEQ ID
No.21. In a
further embodiment, the C514 backbone retains one or more epitopes of CS14.
Such C514
epitopes are preferably selected from the nucleotide sequence encoding SEQ ID
No. 23, the
nucleotide sequence encoding SEQ ID No. 26, and sequences having at least 80%,
at least 85%,
at least 90%, or at least 95% sequence identity or homology with the
nucleotide sequence
encoding SEQ ID No. 23 or SEQ ID No. 26.
[0043] The C57 backbone for purposes of the present disclosure includes any
nucleotide
sequence or amino acid sequence that is associated with the C57 genome from
ETEC, including
any fragment or portion thereof. In one embodiment, the C57 backbone is
selected from the
nucleotide sequence encoding SEQ ID No. 29 and/or a sequence that has at least
80%, at least
85%, at least 90%, or at least 95% sequence identity or homology with a
nucleotide sequence
encoding SEQ ID No.29. In an alternative embodiment, the C57 backbone is
selected from the a
17
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with SEQ ID No.29.
[0044] The CS12 backbone for purposes of the present disclosure includes
any nucleotide
sequence or amino acid sequence that is associated with the CS12 genome from
ETEC, including
any fragment or portion thereof. In one embodiment, the C512 backbone is
selected from the
nucleotide sequence encoding SEQ ID No. 30 and/or a sequence that has at least
80%, at least
85%, at least 90%, or at least 95% sequence identity or homology with the
nucleotide sequence
encoding SEQ ID No.30. In an alternative embodiment, the CS12 backbone is
selected from the
a sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with SEQ ID No.30.
[0045] The CS17 backbone for purposes of the present disclosure includes
any nucleotide
sequence or amino acid that is associated with the CS17 genome from ETEC,
including any
fragment or portion thereof. In one embodiment, the C517 backbone is selected
from the
nucleotide sequence encoding SEQ ID No. 31 and/or a sequence that has at least
80%, at least
85%, at least 90%, or at least 95% sequence identity or homology with the
nucleotide sequence
encoding SEQ ID No.31. In an alternative embodiment, the CS17 backbone is
selected from the
a sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with SEQ ID No. 31.
[0046] The CS19 backbone for purposes of the present disclosure includes
any nucleotide
sequence or amino acid sequence that is associated with the CS19 genome from
ETEC, including
any fragment or portion thereof. In one embodiment, the C519 backbone is
selected from the
nucleotide sequence encoding SEQ ID No. 21 and/or a sequence that has at least
80%, at least
85%, at least 90%, or at least 95% sequence identity or homology with the
nucleotide sequence
18
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
encoding SEQ ID No.32. In an alternative embodiment, the CS19 backbone is
selected from the
a sequence that has at least 80%, at least 85%, at least 90%, or at least 95%
sequence identity or
homology with SEQ ID No. 32.
[0047] The adhesin tip MEFAs disclosed herein may further comprise
additional elements,
where such elements are selected from, but not limited to, heat liable toxin
(LT), heat stable
toxin (STa), epitopes from adhesin of enteroaggregative E.coli (EAEC),
epitopes of cholera,
epitopes of rotavirus and any combination thereof. In one embodiment, there
may be one or
more copies of LT, STa, and any combination thereof.
[0048] For purposes of the present invention, the adhesin tip MEFA may be
comprised of
any nucleotide encoding the backbone of a CFA from ETEC having at least one of
the epitopes
from ETEC inserted therein. One non-limiting example of such an adhesin tip
MEFA is the
nucleotide sequence of SEQ ID No. 1 or the amino acid sequence of SEQ ID No.
20, however,
the disclosure is not so limited as those of skill in the art can appreciate
that many combinations
are possible. In one embodiment, the complete adhesin tip MEFA of the present
invention is a
sequence that is at least 80%, at least 85% at least 90%, at least 95%, or
100% identical to the
nucleotide sequence of SEQ ID No. 1 or the amino acid sequence of SEQ ID No.
20. In another
embodiment, the complete adhesin tip MEFA of the present invention is a
sequence that is at
least 80%, at least 85% at least 90%, at least 95%, or 100% identical to the
nucleotide sequence
of SEQ ID No. 63 or the amino acid sequence of SEQ ID No. 64. In another
embodiment, the
complete adhesin tip MEFA of the present invention is a sequence that is at
least 80%, at least
85% at least 90%, at least 95%, or 100% identical to the nucleotide sequence
of SEQ ID No. 65
or the amino acid sequence of SEQ ID No. 66.
19
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0049] In one aspect, the present disclosure provides for a nucleic acid
molecule that
encodes for the polypeptide molecules described herein.
[0050] Further, the present disclosure provides for an expression vector
comprising the
nucleic acid molecule encoding the polypeptide molecules described herein. The
expression
vector is preferably selected from, but not limited to, E.coli, Salmonella,
and combinations
thereof.
[0051] The E.coli preferably used for purposes of the present disclosure is
selected from,
but not limited to, H10407, THK/38/pEU405, DH5a/pEU588. E116 (E19446), E106
(E11881/9),
UM 75688, JF2423 ETP98066, JF2101, JF2318 ETP050008, CFA/I knockout, 9573,
9474,
9475, 9505, 9504, 9533, 9506, 9468, 9507, 9450, and any combination thereof.
[0052] In another aspect, the present disclosure provides for an
immunogenic composition
or vaccine composition comprising one or more of the adhesin tip MEFAs
encoding polypeptide
molecules described herein and a pharmaceutically acceptable vehicle. The one
or more
polypeptide molecules may be multiple copies of the same polypeptide or more
than one
polypeptide, each having a different structure. It is appreciated that there
are many combinations
of adhesin tip MEFAs encoding polypeptide molecules that may be present in an
immunogenic
composition or vaccine.
[0053] In one embodiment, the immunogenic composition or vaccine disclosed
herein
comprises an adhesin tip MEFA comprising a polypeptide encoding for a
backbone, preferably
the CfaE backbone, having the epitopes for CS1, C52, C53, C54, C55, C56, C521,
and EtpA.
[0054] In a further embodiment, the immunogenic composition or vaccine
disclosed herein
comprises an adhesin tip MEFA comprising a polypeptide encoding for a
backbone, preferably
the C514 backbone, having the epitopes for C57, CS12, CS17, CS14, CS19, and
EaeH.
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0055] In yet another embodiment, the immunogenic composition or vaccine
disclosed
herein comprises two adhesin tip MEFAs. It is appreciated that any combination
of a plurality of
backbones with different epitopes thereon is contemplated in the present
disclosure. In one
preferred embodiment, the first adhesin tip MEFA comprises a polypeptide
encoding for a CfaE
backbone having the epitopes for CS1, CS2, CS3, CS4, CS5, CS6, CS21, and EtpA;
and the
second adhesin tip MEFA comprises a polypeptide encoding for a CS14 backbone
having the
epitopes for C57, CS12, CS17, CS14, CS19, and EaeH.
[0056] The immunogenic composition of the present disclosure may further
comprise a
preservative, stabilizer, carrier, adjuvant, and/or pharmaceutical vehicle.
"Adjuvants" as used
herein, can include aluminum hydroxide and aluminum phosphate, saponins e.g.,
Quil A, Q5-21
(Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals,
Inc.,
Birmingham, AL), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-
water emulsion.
The emulsion can be based in particular on light liquid paraffin oil (European
Pharmacopea
type); isoprenoid oil such as squalane or squalene ; oil resulting from
theoligomerization of
alkenes, in particular of isobutene or decene; esters of acids or of alcohols
containing a linear
alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-
(caprylate/caprate),
glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of
branched fatty acids or
alcohols, in particular isostearic acid esters. The oil is used in combination
with emulsifiers to
form the emulsion. The emulsifiers are preferably nonionic surfactants, in
particular esters of
sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of
polyglycerol, of propylene
glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are
optionally
ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in
particular the Pluronic
products, especially L121. See Hunter et al., The Theory and Practical
Application of Adjuvants
21
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
(Ed.Stewart-Tull, D. E. S.). JohnWiley and Sons, NY, pp51-94 (1995) and Todd
et al., Vaccine
15:564-570 (1997).
[0057] For example, it is possible to use the SPT emulsion described on
page 147 of
"Vaccine Design, The Subunit and Adjuvant Approach" edited by M. Powell and M.
Newman,
Plenum Press, 1995, and the emulsion MF59 described on page 183 of this same
book.
[0058] A further instance of an adjuvant is a compound chosen from the
polymers of
acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl
derivative.
Advantageous adjuvant compounds are the polymers of acrylic or methacrylic
acid which are
cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols.
These compounds are
known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Persons
skilled in the art
can also refer to U. S. Patent No. 2,909,462 which describes such acrylic
polymers cross-linked
with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably
not more than
8, the hydrogen atoms of at least three hydroxyls being replaced by
unsaturated aliphatic radicals
having at least 2 carbon atoms. The preferred radicals are those containing
from 2 to 4 carbon
atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The
unsaturated radicals
may themselves contain other substituents, such as methyl. The products sold
under the name
Carbopol ; (BF Goodrich, Ohio, USA) are particularly appropriate. They are
cross-linked with an
ally' sucrose or with ally' pentaerythritol. Among then, there may be
mentioned Carbopol 974P,
934P and 971P. Most preferred is the use of Cabopol 971P. Among the copolymers
of maleic
anhydride and alkenyl derivative, the copolymers EMA (Monsanto) which are
copolymers of
maleic anhydride and ethylene. The dissolution of these polymers in water
leads to an acid
solution that will be neutralized, preferably to physiological pH, in order to
give the adjuvant
22
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
solution into which the immunogenic, immunological or vaccine composition
itself will be
incorporated.
[0059] Further suitable adjuvants include, but are not limited to, the RIBI
adjuvant system
(Ribi Inc.), Block co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville
CA),
monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin
from E. coli
(recombinant or otherwise), cholera toxin, IMS 1314 or muramyl dipeptide among
many others.
Most preferably, heat-labile enterotoxin mutants are used as the adjuvant.
[0060] In a further aspect, a method of inducing an immune response against
ETEC is
provided. Preferably, the steps of the method include, but are not limited to,
administration of
one or more of the polypeptide(s) described herein to a human or animal in
need thereof.
[0061] A method of reducing the incidence of or severity of clinical signs
of ETEC
infection is also provided in the present disclosure. The method of reducing
the incidence or
severity clinical signs of ETEC infection includes, but is not limited to, the
step of administration
of one or more the polypeptide(s) disclosed herein to a human or animal in
need thereof. In one
embodiment, the severity or incidence of clinical signs of ETEC are reduced by
at least 10%, at
least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least
70%, at least 80%, at
least 90%, and 100% when compared to a human or animal, or group of humans or
animals not
having received the adhesin tip MEFA. The MEFA is preferably administered in
an amount of
less than 50 micrograms, where values such as 1-30 micrograms, 10-30
micrograms, 10-20
micrograms, 10-50 micrograms, 20-50 micrograms, 30-50 micrograms, 40-50
micrograms, 1
microgram, 5 micrograms, 10 micrograms, 15 micrograms, 20 micrograms, 25
micrograms, 30
micrograms, 35 micrograms, 40 micrograms, 45 micrograms, and 50 micrograms are
envisioned.
23
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
The route of administration is preferably selected from intradermal,
intramuscular, or
subcutaneous immunization.
[0062] A method of treating or reducing the incidence or severity of
diarrhea is also
provided in the present disclosure. The method preferably comprises the steps
of administration
of one or more of the adhesin tip MEFA(s) of the present disclosure to a human
or animal, or
group of humans or animals in need thereof. In one embodiment, diarrhea
incidence or severity
is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least
50%, at least 60%, at
least 70%, at least 80%, at least 90%, and 100% when compared to a human or
animal, or group
of humans or animals not having received the administration of the adhesin tip
MEFA.
[0063] A method of reducing the adhesion of ETEC to the gut is also
provided by the
present disclosure. The method preferably comprises the steps of
administration of one of more
of the adhesin tip MEFA(s) of the present disclosure to a human or animal in
need thereof. In
one embodiment, adhesion to the gut is reduced by at least 10%, at least 20%,
at least 30%, at
least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least
90%, and 100% when
compared to a human or animal not having received the adhesin tip MEFA
[0064] As used herein "multiepitope fusion antigen" (MEFA) refers to a
molecule that is
created by combining the fusion and epitope strategies for making vaccines or
immunogenic
compositions. The method of producing an MEFA allows for use of a backbone
molecule and
the addition of any antigenic element or identified virulence factors, as well
as additional
elements. In the present disclosure, the MEFA may have a single copy or
multiple copies of any
one component. The "adhesin tip MEFA" means that the MEFA is created using the
"tip" or end
of the genome or a subunit that is on the "tip" of the gene.
24
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0065] The "adhesin tip" for purposes of the present disclosure refers to a
subunit protein
located at the tip of an ETEC bacteria adhesion.
[0066] For purposes of the present disclosure, "adhesive subunit" refers to
a subunit
protein of ETEC adhesion which is not located at the tip, but is involved in
bacterial adherence to
host receptors.
[0067] For purposes of the present disclosure, "sequence identity" refers
to a relationship
between two or more polypeptide sequences or two or more polynucleotide
sequences, namely a
reference sequence and a given sequence to be compared with the reference
sequence. Sequence
identity is determined by comparing the given sequence to the reference
sequence after the
sequences have been optimally aligned to produce the highest degree of
sequence similarity, as
determined by the match between strings of such sequences. Upon such
alignment, sequence
identity is ascertained on a position-by-position basis, e.g., the sequences
are "identical" at a
particular position if at that position, the nucleotides or amino acid
residues are identical. The
total number of such position identities is then divided by the total number
of nucleotides or
residues in the reference sequence to give % sequence identity. Sequence
identity can be readily
calculated by known methods, including but not limited to, those described in
Computational
Molecular Biology, Lesk, A. N., ed., Oxford University Press, New York (1988),
Biocomputing:
Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York
(1993);
Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H. G.,
eds., Humana
Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge,
G., Academic
Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds.,
M. Stockton
Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied
Math., 48: 1073
(1988), the teachings of which are incorporated herein by reference. Preferred
methods to
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
determine the sequence identity are designed to give the largest match between
the sequences
tested. Methods to determine sequence identity are codified in publicly
available computer
programs which determine sequence identity between given sequences. Examples
of such
programs include, but are not limited to, the GCG program package (Devereux,
J., et al., Nucleic
Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and FASTA (Altschul, S. F.
et al., J.
Molec. Biol., 215:403-410 (1990). The BLASTX program is publicly available
from NCBI and
other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, MD
20894,
Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990), the teachings of
which are
incorporated herein by reference). These programs optimally align sequences
using default gap
weights in order to produce the highest level of sequence identity between the
given and
reference sequences.
[0068] For purposes of the present disclosure, "sequence homology refers to
a method of
determining the relatedness of two sequences. To determine sequence homology,
two or more
sequences are optimally aligned, and gaps are introduced if necessary.
However, in contrast to
"sequence identity", conservative amino acid substitutions are counted as a
match when
determining sequence homology. In other words, to obtain a polypeptide or
polynucleotide
having 95% sequence homology with a reference sequence, 85%, preferably 90%,
even more
preferably 95% of the amino acid residues or nucleotides in the reference
sequence must match
or comprise a conservative substitution with another amino acid or nucleotide,
or a number of
amino acids or nucleotides up to 15%, preferably up to 10%, even more
preferably up to 5% of
the total amino acid residues or nucleotides, not including conservative
substitutions, in the
reference sequence may be inserted into the reference sequence.
26
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0069] For purposes of the present disclosure, "epitope" refers to a short
peptide which
functions as an antigen molecule to induce antibody response.
[0070] For purposes of the present disclosure, "backbone" refers to a
protein that serves as
a support of the molecule to maintain a stable protein structure and also to
present foreign
epitopes of interest.
[0071] The MEFA of the present invention is not a nucleotide or amino acid
sequence
found in nature, as it has been constructed by the hand of man. Therefore, the
MEFA of the
present invention is markedly different from what is found in nature. Similar
to Example 5 for
the Nature-Based Product Examples of eligible subject matter under 35 U.S.C.
101 issued by the
US Patent Office in 2014, the MEFA of the present invention is like claim 2 of
that example
because the MEFA gene has additional elements, such as the epitopes that
provides it with a
functionally different characteristic than naturally occurring ETEC bacteria.
Most notably, the
MEFA of the present invention fails to adhere to the intestine, which is a
marked difference from
ETEC bacteria found in nature.
[0072] All ranges provided herein include each and every value in the range
as well as all
sub-ranges there-in-between as if each such value or sub-range was disclosed.
Further, all
aspects and embodiments of the disclosure comprise, consist essentially of, or
consist of any
aspect or embodiment, or combination of aspects and embodiments disclosed
herein.
[0073] EXAMPLES
[0074] The following examples are simply intended to further illustrate and
explain the
present invention. The invention, therefore, should not be limited to any of
the details in these
examples.
[0075] Example 1:
27
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0076] Materials and Methods
[0077] Bacterial strains and plasmids: E. coli and ETEC strains used as DNA
templates for
PCR amplification of the adhesin tip or adhesive subunit genes of CFA/I, CS1 ¨
CS6, CS21 and
EtpA adhesins and for in vitro antibody adherence inhibition assay, as well as
recombinant E.
coli strains expressing each adhesin tip, adhesive subunit protein and the tip
MEFA-I protein are
listed below in Table 1. Plasmid pET28a (Novagen, Madison, WI) and E. coli
strain BL21 (GE
Healthcare, Piscataway, NJ) were used to express adhesin tips, adhesive
subunits, and the
adhesin tip MEFA-I protein.
[0078] Table 1:
[0079] A list of Escherichia coli strains used in this study. E. coli and
ETEC strains were
used as templates for amplification of adhesin tip genes, and also used in
antibody adherence
inhibition assay. Recombinant E. coli strains expressing each adhesin tip
constructed in this
study were also included.
Strain Relevant characteristics Source
H10407 078:H11; CFA/I, LT, STa Johns Hopkins University
THK38/pEU405 CS 1 Emory University
DH5a/pEU588 C52 Emory University
E116 (E19446) C53, LT, STa University of Gothenburg
E106 (E11881/9) C54/C56, LT, STa University of Gothenburg
UM 75688 C55/C56, LT, STa Johns Hopkins University
28
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
JF2423 ETP98066 CS6, LT, STa Washington University
JF2101 CS21, EtpA, STa Washington University
JF2318 ETP050008 EtpA, STa Washington University
CFA/I knockout ACFA/I H10407, EtpA, LT, STa University of Maryland
9473 CfaE (CFA/I) in pET28a/ BL21 Kant this study
9474 CooD (CS1) in pET28a/ BL21 Kant this study
9475 CotD (C52) in pET28a/BL21 Kant this study
9505 CstH (CS 3) in pET28a/BL21 Kant this study
9504 CsaE (C54) in pET28a/BL21 Kant this study
9533 CsfD (CS 5) in pET28a/BL21 Kant this study
9506 CssB (CS 6) in pET28a/BL21 Kant this study
9468 LngA (C521) in pET28a/BL21 Kant this study
9507 EtpA in pET28a/BL21 Kant this study
adhesin tip MEFA-I in pET28a/BL21 this study
9450
Kant
[0080] Cloning and expression of adhesin tips, adhesive subunits and
adhesin tip MEFA-I:
PCR primers used to amplify the adhesin tip genes of CFA/I, CS1, C52, C53, C54
and C55, and
adhesive subunit (major structural subunit involving in adhesion) genes of
C56, C521 and EtpA,
29
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
are listed in Table 2. PCR amplified adhesin tip or adhesive subunit gene
products were digested
with restriction enzymes Eagl and Ncol or Nhel (New England BioLabs Inc,
Ipswich, MA).
Digested products were cloned into vector pET28a and expressed in E. coli
strain BL21.
[0081] Table 2:
[0082] PCR primers used to amplify adhesin tip subunits in this study.
Restriction sites,
Nhel or Ncol in forward primers and Eagl in reverse primers, are underlined.
Primer Sequence (5' ¨> 3')
CfaE-F CTAGCTAGCGATAAAAATCCCGGAAGTG (SEQ ID No. 18)
CfaE-R GATCGGCCGCTAGAGTGTTTGACTACTTG (SEQ ID No. 19)
CS1 (CooD)-F CTAGCTAGCGGGCGATACCCGGAAACTACAG (SEQ ID No. 3)
CS1 (CooD)-R GATCGGCCGTCATAAATTTTCGACACTGG (SEQ ID No. 4)
C52 (CotD)-F CTAGCTAGCCAATCATGGCATACGAACGTAG (SEQ ID No. 5)
C52 (CotD)-R GATCGGCCGTTACAGACTTGAACTACTAGGAG (SEQ ID No. 6)
AGTTACATCCATGGGCACTCTAACCAAAGAACTGGCATTAAATGTGC
C53 (CstH)-F
(SEQ ID No. 7)
TACATGATCGGCCGTTAATTACCTGAAACTAAATGTTCGTTACC (SEQ
C53 (CstH)-R
ID No. 8)
C54 (CsaE)-F CTAGCTAGCGATAAAATTCCCGGAGATGAAAG (SEQ ID No. 9)
C54 (CsaE)-R GATCGGCCGCTAGAGTGTTTGACTACTTGGTGTG (SEQ ID No. 10)
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CS5 (CsfD)-F TTTTCCATGGTTATGGTTCAGGCTGCTACA (SEQ ID No. 11)
C55 (CsfD)-R AGATCGGCCGTTATTTATTGTAACATTTCC (SEQ ID No. 12)
AGTTACATCCATGGGCTGGCAATATAAATCTCTGGATGTAAATG (SEQ
C56 (CssB)-F
ID No. 13)
ATGTAGATCGGCCGTTAAGTCAAATTTCCTGCATAAGTACCAGAC
C56 (CssB)-R
(SEQ ID No. 14)
C521 (LngA)-F CTAGCTAGCATGAGCCTGCTGGAAGTTATCATTG (SEQ ID No. 15)
C521 (LngA)-R GATCGGCCGTTAACGGCTACCTAAAGTAATTG (SEQ ID No. 16)
EtpA-F CTAGCTAGCGGCGTGGGTAATGCAAAAGCCACG (SEQ ID No. 17)
ATGTAGATCGGCCGTTAGCTGAAGGTGTAACGACGGTTCATG (SEQ ID
EtpA-R
No. 34)
[0083] To construct the adhesin tip MEFA-I gene, first web-based B-cell
epitope
prediction software was used to in silico identify B-cell epitopes from the
adhesin tips of the six
adhesins (CFA/I, CS1-055) and adhesive subunits of three adhesins (C56, C521,
EtpA). Then
the CFA/I tip CfaE gene (cfaE) was applied as backbone, then eight nucleotide
fragments coding
surface-exposed but less antigenic peptides were truncated, as confirmed by
DNA sequencing,
and the nucleotide fragments coding the most antigenic epitope of the other
eight adhesin tips or
adhesive subunits were inserted into the truncated positions of the cfaE gene.
After in silico
optimization of epitope presentation, this adhesin tip MEFA-I gene was
synthesized (gene
31
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
synthesis performed by Genewiz, South Plainfield, NJ). The synthetic gene was
digested with
enzymes Ncol and Eagl, and were cloned in vector pET28a and expressed in E.
coli BL21.
[0084] A single colony from each recombinant strain was cultured in 5 ml
Luria-Bertani
(LB) broth supplemented with kanamycin (30 g/m1) at 37 C overnight. Overnight
grown
culture was added to 200 ml 2x YT medium (2x Yeast Extract Tryptone). After
optical density
(OD) reached 0.6, bacteria were induced with 0.1 mM Isopropyl 3-D-1-
thiogalactopyranoside
(IPTG; Sigma, St. Louis, MO) and grew for four more hours. Bacteria were
collected with
centrifugation of 12,000 - 13,000 rpm for 15 minutes. Pellets, after frozen
and thaw, were
suspended in 10 ml bacterial protein extraction reagent (B-PER; Pierce,
Rockford, IL) with
vortex. After 30 min at room temperature, bacteria lysates were centrifuged at
12,000 - 13,000
rpm for 15 min at 4 C. Pellets were suspended in 10 - 20 ml B-PER with
vigorous vortex and
pipetting with a 20-ml syringe, mixed with 200 - 400 1 freshly prepared
lysozyme (10 mg/ml, in
B-PER), and incubated at room temperature for 20 min. Suspensions were
centrifuged; resultant
pellets were suspended and then incubated with lysozyme again. After
centrifugation, pellets
were suspended in 100 ml 1:10 diluted B-PER, vortexed, and centrifuged.
Pellets were washed
three times with 100 ml PBS, vortexed vigorously, centrifuged at 12,000 rpm
for 15 min at 4 C.
Final pellets were dissolved in 10 ml PBS.
[0085] Extracted proteins were then refolded using a protein refolding kit
by following
manufacturer's protocol (Novagen). Refolded solubilized proteins were
transferred to molecular
porous membrane tubing (Spectrum Laboratories, Inc., Rancho Dominguez, CA),
and dialyzed
in 20 mM Tris-HC1, pH8.5 (supplemented with 0.1 mM DTT) at 4 C. After 3 ¨ 4 h,
protein
samples were moved to dialysis buffer without DTT, and followed by two more
buffer changes.
32
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
Solubilized proteins (in supernatant) were collected with centrifugation at
12,000 rpm for 10 min
at 4 C, and were stored at -80 C.
[0086] Mouse immunization with adhesin tip MEFA-I was performed by the
following
steps. Before being used in mouse immunization, 25 or 30 1 refolded
solubilized adhesin tip
MEFA-I protein samples (1 mg/ml) were examined in 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with mouse anti-CFA/I antiserum
(1:3000).
IRDye-labeled goat anti-mouse IgG (1:5000; LI-COR, Lincoln, NE) was used as
the secondary
antibody. LI-COR Odyssey premium infrared gel imaging system was used to
visualize bound
proteins. In addition, Coomassie blue staining was used to assess purity of
the extracted adhesin
tip MEFA-I proteins.
[0087] Seven-week-old female BALB/c mice (Charlies River Laboratories
International,
Inc., Wilmington, MA) were used in mouse immunization. A group of eight mice
were each
intraperitoneally immunized with 150 lug (in 200 1 PBS) adhesin tip MEFA-I
protein generated
above, together with liug dmLT (LTR192G/L211A; provided by Walter Reed Army
Institute of
Research, Silver Spring, MD) as adjuvant. Immunized mice received two booster
injections
intraperitoneally at the same dosage amount of the primary, in an interval of
two weeks. Two
weeks after the second booster, mice were sacrificed. A group of eight mice
without
immunization were served as the control group.
[0088] Serum samples were collected from each mouse before the primary and
two weeks
after the final booster, and were stored at -80 C until use. The mouse
immunization study
complied with the American Welfare Act by following the 1996 National Research
Council
guidance and was approved by the Kansas State University's Institutional
Animal Care and Use
Committee.
33
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[0089] Mouse anti-CFA IgG antibody titration was performed by the following
steps.
Recombinant adhesin tip and adhesive subunit proteins were used as coating
antigens
respectively in ELISAs to titrate mouse serum anti-CfaE (CFA/I), -CooD (CS1), -
CotD (C52), -
CstH (C53), -CsaE (C54), -CsfD (C55), -CssB (C56), anti-LngA (C521) and anti-
EtpA IgG
antibodies in this study. Serum samples collected from each mouse prior to the
primary
immunization and two weeks after the final booster were initially diluted in
1:400 and then two-
folded diluted till to 1:51,200. Four hundred nanogram of each adhesin tip or
subunit
recombinant protein, in 100 pl coating buffer (41), was added to each well of
Immulon 2HB 96-
well plates (Thermo Fisher Scientific, Rochester, NY). Plates were incubated
at 37 C for 1 h
and then 4 C overnight. Coated plates were washed three times with PBS-0.05%
Tween 20
(PBST), and uncoated sites were blocked with 5% nonfat milk at 37 C for 1 h.
After washing
three times with PBST, wells were incubated with mouse serum dilutions at 37 C
for 1 hour.
After washing 3 times with PBST, wells were incubated with horseradish
peroxidase (HRP)
conjugated goat-anti-mouse IgG antibodies (1:3000; Sigma) at 37 c for 1 h.
After 3 washes with
PBST and 2 washes with PBS, wells were incubated with 100 1 3,3',5,5'-
tetramethylbezidine
(TMB) Microwell Peroxidase Substrate (KPL, Gaithersburg, MD) at room
temperature for 30
min, and were measured for optical density (OD) at 650-nm wavelength. OD
readings from the
highest dilution that gave readings above 0.3 after subtraction of background
readings (OD x
dilution) were calculated to antibody titers and presented in logio scale.
[0090] A mouse serum antibody adherence inhibition assay was performed by
the
following steps. Mouse serum in vitro antibody adherence inhibition assay was
carried out.
Briefly, 30 pl serum pooled from the immunized mice or the control mice was
added to ETEC or
E. coli bacteria (4.5x106 CFUs; in 150 1 PBS) that express CFA/I, CS1, C52,
C53, C54/C56,
34
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CS5/CS6, CS6, CS21, or EtpA. Incubated at room temperature for 1 h on a shaker
(50 rpm), the
serum/bacteria mixture was brought to 300 1 with PBS and added to Caco-2
cells (3x105 cells,
in 700 1 DMEM-10% FBS; at a multiplicity-of-infection ratio of 15 bacteria to
1 cell). After
incubation at 37 C for 1 h in a CO2 incubator (5% CO2), Caco-2 cells were
gently washed 3
times with PBS to remove non-adherent bacteria, and then dislodged with 0.5%
triton X (300 1
per well; 37 C for 20 min at room temperature). Adherent bacteria (and
dislodged Caco-2 cells)
were collected with centrifugation, suspended in 1 ml PBS, serially diluted
and plated on LB
plates. Plates were cultured at 37 C overnight, and counted for CFUs.
[0091] Statistical analysis: Data of antibody adherence inhibition assay
were analyzed
using the mixed procedure (SAS for windows, version 8; SAS Institute, Cary,
NC). Results were
expressed in means standard deviations. Student's t-test was used to compare
differences
between the immunization group and the control group. Differences were
considered significant
if p <0.05 when treatments were compared at two-tailed distribution and two-
sample unequal
variance.
[0092] Results and Conclusions
[0093] Adhesin tip MEFA-I protein carried epitopes of nine adhesin tips or
subunits.
Epitopes `QFTEKRSLIKR' (CS1/SEQ ID No. 37), `SQSIEMRFQDDSQ' (C52/SEQ ID No.
42), `NITLDKNAGNT' (C53/SEQ ID No. 36), TYLRKINDDTK' (C54/SEQ ID No. 41),
`DIGRLQSDAEY' (C55/SEQ ID No. 35), `YDSDPKLDSQ' (C56/ SEQ ID No. 38),
NAMKDAYQRDGKYPDF' (C521/SEQ ID No. 39), and `VEGEKSPRRGV' (EtpA/SEQ ID
No. 40) were in silico predicted from CooD of CS1, CotD of C52, CstH of C53,
CsaE of C54,
CsfD of C55, CssB of C56, LngA of C521 and EtpA of EtpA , respectively. Three
epitopes
from CfaE of CFA/I: `TEKRSLIKRELQIK' (SEQ ID No. 43),
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
`QDDNSKSDGKFYLKKINDDSKE' ( SEQ ID No. 44) and `12LQLDAKVKNPEA' (SEQ ID
No. 45) were retained in the tip MEFA-I (Fig. 1). This 362-amino acid
polypeptide was
expressed, extracted, and recognized by mouse anti-CFA/I antiserum (Fig 1).
[0094] It was found that mice intraperitoneally immunized with the adhesin
tip MEFA-I
developed immune responses to all nine adhesins. All eight mice
intraperitoneally immunized
with the adhesin tip MEFA-I recombinant protein developed antibody responses
to each of the
nine adhesin tips or adhesive subunits (Fig. 2). Anti-CfaE, -CooD, -CotD, -
CstH, -CsaE, -CsfD,
-CssB, and -LngA and anti-EtpA IgG antibody titers in the immunized mice were
3.1 0.36, 3.8
0.10, 3.2 0.19, 3.5 0.14, 3.8 0.13, 3.5 0.19, 4.0 0.16, 3.9 0.04
and 4.0 0.13 (in
logi0), respectively. No antibody titers to these adhesin tip or subunit
antigens were detected in
the serum samples of the control mice, or serum collected before the primary
immunization.
[0095] It was further discovered that mouse serum antibodies inhibited
adherence of ETEC
or E. coli bacteria expressing these nine adhesins. ETEC bacteria expressing
CFA/I, C53,
C54/C56, C55/C56, C56, C521 or EtpA, or H10407 CfaE knock out mutant which
expresses
EtpA, and recombinant E. coli strains expressing CS1 or C52 showed significant
reduction in
adherence to Caco-2 cells, after being incubated with the pooled serum sample
of the immunized
mice, compared to the same bacteria incubated with the pooled serum of the
control mice.
[0096] Discussion
[0097] The adhesin tip MEFA-I created from this study carried epitopes from
nine
different ETEC adhesins and induced antibody responses to each of these nine
adhesins. That
may rejuvenate the concept of epitope vaccinology for developing safe and
broadly protective
vaccines against immunologically heterogeneous pathogens. Differing from the
conceptual
epitope vaccine strategy that stacks multiple epitopes into a linear peptide
antigen and often leads
36
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
to inferior immunogenicity or protection, the present disclosure applied the
MEFA (multiepitope
fusion antigen) approach to use a backbone protein and to substitute surface-
exposed peptides of
the backbone protein with epitopes of foreign antigens. This MEFA approach
results in a protein
which better presents the antigenic epitopes of interest. Future protein
structural studies will
help to understand antigenic topology of this MEFA-I protein.
[0098] The present disclosure included a CssB epitope to represent CS6
adhesin in this tip
MEFA construction. Both CssA and CssB are the major structural subunits and
play key roles in
CS6 adherence. CssA epitope `72QVTVYPV78, (SEQ ID No. 54) was found capable of
inducing
in vitro protective antibodies against C56 adhesin adherence. Data from this
study showed that
the CssB epitope `YDSDPKLDSQ' (SEQ ID No. 52) also induced antibodies that
inhibited C56
adherence to Caco-2 cells.
[0099] CstH is the major structural subunit and also the adhesive subunit
for C53 adhesin.
CstH epitope `NITLDKNAGNT' (SEQ ID No. 49) in this tip MEFA-I was able to
induce strong
anti-CstH antibody response. Comparison of antibody titers derived from the
major subunit
MEFA-I and this tip MEFA-I may not be much informative since different coating
antigens were
used in antibody titration ELISAs. In vitro antibody adherence inhibition
assays suggested
antibodies derived against these two CstH epitopes showed similar rates (50%
vs. 58% from
anti-CFA MEFA-I antibodies and anti-adhesin tip MEFA-I antibodies) inhibiting
adherence of
C53 adhesin to Caco-2 cells. Future studies to identify optimal epitopes for
ETEC adhesin tips or
major subunits will help to improve efficacy of vaccine candidates.
[00100] Results from this study showed that the adhesin tip MEFA-I carried
adhesin tip or
adhesive subunit epitopes induced antibody responses to nine ETEC adhesins,
and derived
antibodies inhibited adherence of E. coli and ETEC bacteria expressing these
nine adhesins to
37
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
Caco-2 cells. Future studies using different immunization routes, different
animals and
challenge studies will be needed to further characterize antigen antigenicity
and potential vaccine
application against ETEC diarrhea.
[00101] Example 2
[00102] Materials and Methods
[00103] The method described above will be completed for another embodiment
of the
present disclosure, an adhesin tip MEFA (tip MEFA-I utilizing the backbone of
CS14 having
epitopes for C57, CS12, CS17, CS14, CS19, and EaEH.
[00104] Table 3. This table shows the sequences of the complete MEFA-II
sequence, as
well as its constituent elements.
Adhesin Tip MEFA-II (final product for 6 adhesins) (SEQ ID No. 20)
MNKILFIFTLFFSSVLFTFAVS AQEGSSNRAKIDQTGDYTNIFGPRDRNESSPKHNILNDYI
TAYSESHTLYDRMIFLCLSS QNTLNGACPTSENPS S S S VS GETNITLQFTEKRS LIKRELQI
KGYKRLLFKGANCPSYLTLNS AHYNKDGEGVS PGGAS LYLYIPAGELKNLPFGGIWD AT
LKLRVKRRYDQTYGTYTINITVKLTDKGNIQIWLPQFKS D ARVDLNLS FQAPRQDRSVQ
S GRNSVDMCFYDGYSTNS S SLELRFQDNNPKSDGKFYLRKINDDTKEIAYTLSLLLAGK
SAGNKKPIWENQSCDNIADAASLEINWNRITAVTMPEISVPVLCWPGRLQLDAKKSPDIE
DYQERPANGYMGNINITFTPSS QTL
Note: underlined amino acids are the epitopes from the tips of 6 adhesins.
CS14 ¨ CsuD Backbone:
C514 Amino Acid (386) (SEQ ID No., 21)
MNKILFIFTLFFSSVLFTFAVS AD KIPGDENITNIFGPRDRNES S PKHNILNDYITAYS ES HT
LYDRMIFLCLSS QNTLNGACPTSENPS S S S VS GETNITLQFTEKRS LIKRELQIKGYKRLLF
KGANCPSYLTLNS AHYTCNRNS AS GAS LYLYIPAGELKNLPFGGIWD AT LKLRVKRRYD
QTYGTYTINITVKLTDKGNIQIWLPQFKSDARVDLNLRPTGGGTYIGRNSVDMCFYDGY
STNS S S LELRFQDNNP KS DGKFYLRKINDDTKEIAYT LS LLLAGKS LTPTNGT S LNIAD AA
SLEINWNRITAVTMPEISVPVLCWPGRLQLDAKVENPEAGQYMGNINITFTPSS QTL
Epitopes predicted: 23-33, 84-99, 141-150, 221-231, 255-264, 289-299, 336-346.
Replacement Epitopes substituted for predicted epitopes above.
38
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CS7: QEGSSNRAKIDQTGDY 24-39 (SEQ ID No. 22)
CS14: PTSENPSSSSVSGETN 91-106 (retained from the backbone) (SEQ ID No. 23)
CS12: NKDGEGVSPG 149-158 (SEQ ID No. 24)
CS17: SFQAPRQDRSVQS 231-243 (SEQ ID No. 25)
CS14: QDNNPKSDGK; 268-277 (SEQ ID No. 26)
CS19: AGNKKPIWENQSCD 303-316 (SEQ ID No. 27)
EaEH: KKSPDIEDYQERPANG 355-370 (SEQ ID No. 28)
C514 tip CSuD Backbone Nucleotide sequence (SEQ ID NO. 109)
ATGAATAAGATTTTATTTATTTTTACATTGTTTTTCTCTTCAGTACTTTTTACATTTGC
TGTATCGGCAGATAAAATTCCCGGAGATGAGAATATAACTAATATTTTTGGCCCGCG
TGACAGGAACGAATCTTCCCCCAAACATAATATATTAAATGACTATATTACAGCATA
CAGTGAAAGTCATACTCTGTATGATAGGATGATTTTTTTATGTTTGTCTTCTCAAAAT
ACACTTAATGGAGCATGTCCAACCAGTGAGAATCCTAGCAGTTCATCGGTCAGTGGC
GAAACAAATATAACATTACAATTTACGGAAAAAAGAAGTTTAATTAAAAGAGAGCT
ACAAATTAAAGGCTATAAACGATTATTGTTCAAAGGTGCTAACTGCCCATCCTACCT
AACACTTAACTCAGCTCATTATACCTGCAATAGAAACTCGGCTTCAGGTGCAAGTTT
ATATTTATATATTCCTGCTGGCGAACTAAAAAATTTACCTTTTGGTGGTATCTGGGAT
GCTACTCTGAAGTTAAGAGTAAAAAGACGATATGATCAGACCTATGGAACTTACAC
TATAAATATCACTGTTAAATTAACTGATAAGGGAAATATTCAGATATGGTTACCTCA
GTTCAAAAGTGACGCTCGCGTCGATCTTAACTTGCGTCCAACTGGTGGGGGCACATA
TATTGGAAGAAATTCTGTTGATATGTGCTTTTATGATGGATATAGTACTAACAGCAG
CTCTTTGGAGCTAAGATTTCAGGATAACAATCCTAAATCTGATGGGAAATTTTATCT
AAGGAAAATAAATGATGACACCAAAGAAATTGCATATACTTTGTCACTTCTCTTGGC
GGGTAAAAGTTTAACTCCAACAAATGGAACGTCATTAAATATTGCTGACGCAGCTTC
TCTGGAAATAAACTGGAATAGAATTACAGCTGTCACCATGCCAGAAATCAGTGTTCC
GGTGTTGTGTTGGCCTGGACGTTTGCAATTGGATGCAAAAGTGGAAAATCCCGAGGC
CGGACAATATATGGGTAATATTAATATTACTTTCACACCAAGTAGTCAAACACTCTA
G
CS7 ¨ Cs213 (SEQ ID No. 29)
MKNKLLFMMLTILGAPGIAAAAGYDLANSEYNFAVNELS KS S FNQAAIIGQAGTNNS AQ
LRQGGS KLLAVVAQEGSSNRAKIDQTGDYNLAYIDQAGS ANDASISQGAYGNTAMIIQK
GS GNKANITQYGTQKTAIVVQRQS QMAIRVTQR
Epitope [73-88 (16)]: QEGSSNRAKIDQTGDY (SEQ ID No. 22)
C512 ¨ CswF (SEQ ID No. 30)
39
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
MLKRISCIIFVFFSGLIYAAEITNQIELSVKVNISKPMCKLNSGTQTIDFGDFDVLDIITENR
KLNGHATFKFTECSSVKNMKIKFKQAGQNPALDIVNNYIPNSKGDRMAKGVAVKLLDD
KKQEIQLNKEMNVIVEESLTFKDLTLNAQVISINKDGEGVSPGLLQTAIGMEISYE
Epitope (155-164): NKDGEGVSPG (SEQ ID No. 24)
C512 ¨ CswF Nucleotide Sequence (SEQ ID No. 110)
atgttgaaaag aatatcgtgt ataatttttg tttttttttc
agggctgatt tatgctgcgg aaattacaaa tcagatagag ctttcggtaa aggttaatat
atctaagcct atgtgtaaac ttaattctgg aacgcaaaca atagacttcg gcgattttga
tgtactggat attattacgg agaacagaaa attaaatggt catgcgacct ttaaatttac
tgagtgtagt tctgtcaaaa acatgaagat aaaatttaaa caggcaggac aaaatccagc
gttagatatc gtaaacaatt atatccctaa tagtaaggga gatagaatgg caaagggggt
agcggtaaag cttctggatg ataaaaagca agaaattcaa ctgaacaagg aaatgaatgt
tattgtggag gagagtctga catttaaaga tttaacgtta aatgctcagg ttatctctat
taataaagac ggagagggag tttcacctgg gctacttcag accgcaatag gaatggagat
atcctatgaa tga
Primers to amplify the segment for coating antigen in antibody titration ELISA
RN-CS12-F: ATA TCC ATG GCT ATG TGT AAA CTT AAT TCT GGA (SEQ ID No. 114)
RN-CS12-R: ATC TCG GCC GCT ATT GCG GTC TGA AGT AGC (SEQ ID No. 115)
CS17 ¨ CsbD (SEQ ID No. 31)
MKKIFIFLSIIFS AVVS AGRYPETTVGNLTKSFQAPRQDRSVQSPIYNIFTNHVAGYSLSHN
LYDRIVFLCTSSSNPVNGACPTLGTSGVQYGTTTITLQFTEKRSLIKRNINLAGNKKPIWE
NQSCDTSNLMVLNS KSWSCGHYGNANGTLLNLYIPAGEINKLPFGGIWEATLILRLSRY
GEVSSTHYGNYTVNITVDLTDKGNIQVWLPGFHSNPRVDLNLHPIGNYKYSGSNSLDMC
FYDGYSTNSDSMVIKFQDDNPTYSSEYNLYKIGGTEKLPYAVSLLMGEKIFYPVNGQSFT
INDSSVLETNWNRVTAVAMPEVNVPVLCWPARLLLNADVNAPDAGQYSGQIYITFTPS
VENL
Epitope (32-44): SFQAPRQDRSVQS (SEQ ID No. 25)
C517 CsbD Nucleotide Sequence (SEQ ID No. 111)
atgaaaa agatatttat ttttttgtct atcatatttt
ctgcggtggt cagtgccggg cgatacccgg aaactacagt aggtaatctg acgaagagtt
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
ttcaagcccc tcgtcaggat agaagcgtac aatcaccaat atataacatc tttacgaatc
atgtggctgg atatagtttg agtcataact tatatgacag gattgttttt ttatgtacat
cctcgtcgaa tccggttaat ggtgcttgcc caacccttgg aacatctgga gttcaatacg
gtactacaac cataaccttg cagtttacag aaaaaagaag tctgataaaa agaaatatta
atcttgcagg taataagaaa ccaatatggg agaatcagag ttgcgacact agcaatctaa
tggtgttgaa ttcgaagtct tggtcctgtg ggcattacgg aaatgctaac ggaacacttc
taaatctgta tatccctgca ggagaaatca acaaattgcc ttttggaggg atatgggagg
caactctgat cttacgotta tcaagatatg gcgaagtcag tagcacccat tacggcaatt
ataccgtaaa tattacggtt gatttaactg ataaaggtaa tattcaggta tggcttccag
ggtttcacag caacccgcgt gtagacctga atctgcaccc tatcggtaat tataaatata
gtggtagtaa ttcactcgac atgtgtttct atgatggata tagtacaaac agtgatagca
tggtaataaa gttccaggat gataatccta cctattcatc tgaatataat ctttataaga
tagggggcac tgaaaaatta ccatatgctg tttcactgct tatgggagaa aaaatatttt
atccagtgaa tggtcaatca tttactatca atgacagtag tgtactcgaa acaaactgga
atcgagtaac cgcagttgct atgccggaag ttaatgttcc agtattatgc tggccagcaa
gattgctatt aaatgctgat gtaaatgctc ccgatgcagg acagtattca ggacagatat
ataracatt tacacccagt gtcgaaaatt tatga
Primers to amplify the segment for coating antigen in antibody titration ELISA
RN-CS17-F: TTT TCC A Ri 06C ATG AAA AAG ATA TTT ATT TTT (SEQ ID No. 116)
RN-CS17-R: GGT GC'S GCC OTT ATA TAT ATC TGT CCT GAA (SEQ ID No. 117)
CS19 ¨ CsdD (SEQ ID No. 32)
MKKIFIFLSIIFS AVVS AGRYPETTVGNLTKS FQAPRLDRS VQS PIYNIFTNHVAGYS LS HR
LYDRIVFVCTSSSNPVNGACPTIGTSRVEYGTTTITLQFTEKRSLIKRNINLAGNKKPIWEN
QS CDTS NLMVLNS KS WS CGALGNANGTLLNLYIPAGEINKLPFGGIWEATLILRLS RYGE
VS S THYGNYTVNITVDLTDKGNIQVWLPGFHS NPRVDLNLHPIGNYKYS GS NS LDMCFY
DGYSTNSDSMVIKFQDDNPTNSSEYNLYKIGGTEKLPYAVSLLMGGKIFYPVNGQSFTIN
DS S VLETNWNRVT AVAMPEVNVPVLCWPARLLLNADVNAPDAGQYS GQIYITFTPS VE
NL
Epitope (115-128): AGNKKPIWENQSCD (SEQ ID No. 27)
C519 ¨ CsdD (SEQ ID No. 112) Nucleotide Sequence
atgaaaaa gatatttatt tttttgtcta tcatattttc tgcggtggtc
agtgccgggc gatacccgga aactacagta ggtaatctga cgaagagttt tcaagcccct
cgtctggata gaagcgtaca atcaccaata tataacatct ttacgaatca tgtggctgga
tatagtttga gtcatagatt atatgacagg attgtttttg tatgtacatc ctcgtcgaat
ccggttaatg gtgcttgccc aaccattgga acatctagag ttgaatacgg tactacaacc
ataaccttgc agtttacaga aaaaagaagt ctgataaaaa gaaatattaa tcttgcaggt
aataagaaac caatatggga gaatcagagt tgcgacacta gcaatctaat ggtgttgaat
tcgaagtctt ggtcctgtgg ggctctagga aatgctaacg gaacacttct aaatctgtat
41
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
atccctgcag gagaaatcaa caaattgcct tttggaggga tatgggaggc aactctgatc
ttacgcttat caagatatgg cgaagtcagt agcacccatt acggcaatta taccgtaaat
attacggttg atttaactga taaaggtaat attcaggtat ggcttccagg gtttcacagc
aacccgcgtg tagacctgaa tctgcaccct atcggtaatt ataaatatag tggtagtaat
tcactcgaca tgtgtttcta tgatggatat agtacaaaca gtgatagcat ggtaataaag
ttccaggatg ataatcctac caattcatct gaatataatc tttataagat agggggcact
gaaaaattac catatgctgt ttcactgctt atgggaggaa aaatatttta tccagtgaat
ggtcaatcat ttactatcaa tgacagtagt gtactcgaaa caaactggaa tcgagtaacc
gcagttgcta tgccggaagt taatgttcca gtattatgct ggccagcaag attgctatta
aatgctgatg taaatgctcc cgatgcagga cagtattcag gacagatata tataacattt
acacccagtg tcgaaaattt atga
Primers to amplify the segment for coating antigen in antibody titration ELISA
RN-CS19-F: GTC ACC, ATU CAT ATG ACA GGA TTG TTT TTG TAC (SEQ ID No. 118)
RN-CS19-R: GGT GCS CFCC OTT ATA TAT ATC TGT CCT GAA (SEQ ID No. 119)
EaeH (SEQ ID No. 33)
MSHYKTGHKQPRFRYSVLARCVAWANISVQVLFPLAVTFTPV
MAARAQHAVQPRLSMGNTTVTADNNVEKNVASFAANAGTFL
SSQPDSDATRNFITGMATAKANQEIQEWLGKYGTARVKLNVD
KDFSLKDSSLEMLYPIYDTPTNMLFTQGAIHRTDDRTQSNIGF
GWRHFSGNDWMAGVNTFIDHDLSRSHTRIGVGAEYWRDYLKL
SANGYIRASGWKKSPDIEDYQERPANGWDIRAEGYLPAWPQL
GASLMYEQYYGDEVGLFGKDKRQKDPHAISAEVTYTPV
Epitope (222-237): KKSPDIEDYQERPANG (SEQ ID No. 28)
EaeH Nucleotide Sequence (SEQ ID No. 113)
ATGTCACATTATAAAACAGGTCATAAACAACCACGATTTCGTTATTCAGTTCTGGCC
CGCTGCGTGGCGT
GGGCAAATATCTCTGTTCAGGTTCTTTTTCCACTCGCTGTCACCTTTACCCCAGTAAT
GGCGGCACGTGC
GCAGCATGCGGTTCAGCCACGGTTGAGCATGGGAAATACTACGGTAACTGCTGATA
ATAACGTGGAGAAA
AATGTCGCGTCGTTTGCCGCAAATGCCGGGACATTTTTAAGCAGTCAGCCAGATAGC
GATGCGACACGTA
42
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
ACTTTATTACCGGAATGGCCACAGCTAAAGCTAACCAGGAAATACAGGAGTGGCTC
GGGAAATATGGTAC
TGCGCGCGTCAAACTGAATGTCGATAAAGATTTCTCGCTGAAGGATTCTTCGCTGGA
AATGCTTTATCCG
ATTTATGATACGCCGACAAATATGTTGTTCACTCAGGGGGCAATACATCGTACAGAC
GATCGTACTCAGT
CAAATATTGGTTTTGGCTGGCGTCATTTTTCAGGAAATGACTGGATGGCGGGGGTGA
ATACTTTTATCGA
TCATGATTTATCCCGTAGTCATACCCGCATTGGTGTTGGTGCGGAATACTGGCGCGA
TTATCTGAAACTG
AGCGCCAATGGTTATATTCGGGCTTCTGGCTGGAAAAAATCGCCGGATATTGAGGAT
TATCAGGAACGCC
CGGCGAATGGCTGGGATATTCGTGCTGAGGGCTATTTACCCGCCTGGCCGCAGCTTG
GCGCAAGCCTGAT
GTATGAACAGTATTATGGCGATGAAGTCGGGCTGTTTGGTAAAGATAAGCGCCAGA
AAGACCCGCATGCT
ATTTCTGCCGAGGTGACCTATACGCCAGTGCC
Primers to amplify the segment for coating antigen in antibody titration ELISA
RN-EaEH-F: TTT ACC ATC.i CTA ATG GCG GCA CGT GCG CAG CAT (SEQ ID No. 120)
RN-EaEH-R: TTT CCG GC:C GTT ATC TTT ACC AAA CAG CCC (SEQ ID No. 121
[00105] Results and Conclusions:
[00106] Adult female Balb/C mice subcutaneously immunized with 40 lug tip
MEFA-IL
with 2 lug dmLT (double mutant LT, LTR192G/L211A) adjuvant, one primary and
two boosters at an
interval of two weeks, developed antibody responses to CS12, CS14, CS17, C519
and EaeH
adhesins (Fig. 5). No antigen-specific antibody response was detected in the
control mice.
[00107] Figure 5 shows mouse serum IgG antibody titers (logi0), where mice
immunized
with adhesion tip MEFA-II developed anti-CS12, anti-CS14, anti-CS17, and anti-
EaeH IgG
antibodies. Each dot in Figure 5 represented IgG titer from an individual
mouse, where the bars
indicate mean IgG titers.
43
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
[00108] ETEC field isolates expressing CS12, CS14, CS17, CS19 or EaeH, after
incubated with serum of mice SC immunized with the adhesin tip MEFA-II, showed
significant
reduction in adherence to Caco-2 cells, compared to ETEC strains incubated
with serum of the
control mice. That suggested serum antibodies of the immunized mice were
neutralizing,
inhibited adherence of ETEC bacteria expressing any of these five adhesins.
[00109] Table 4. Results from mouse serum antibody in vitro adherence
inhibition
assays. Caco-2 cells (5x105) were incubated with each ETEC bacteria strain
expressing a
different adhesin (in PBS), ETEC bacterial premixed with serum of the control
mice, or ETEC
bacteria premixed with serum of the mice immunized with adhesin tip MEFA-II.
ETEC strains serum of control mice serum of immunized
mice
3276, CS12/CS20/LT/STa (x103) 227.6 21.2 156 17.1 p=0.01
E7476A, CS14 (x102) 91.8 7.0 63.4 6.3 p<0.01
E20738A, CS17 (x102) 137.2 8.1 19.4 3.0 p<0.001
D526-1, CS19 (x102) 92.2 6.7 70.2 9.2 p=0.02
H10407-EaeH/EtpA/CFA/I/LT/STa (x102) 126.6 32.4 67.2 15.3 p=0.04-
[00110] Example 3
[00111] The method described in Example 1 above will be completed for
another
embodiment of the present disclosure, a major subunit CFA MEFA-II utilizing
the backbone of
C521 having epitopes for CS19, CS17, EtpA, CS14, C57, CS12, and EaeH.
[00112] Materials and Methods
[00113] This CFA MEFA-II used C521 major subunit LngA as the backbone, and
has LngA
surface-exposed and less antigenic epitopes substituted by the most antigenic
epitopes from the
major subunits of C57, CS12, CS14, CS17, CS19, EtpA and EaeH adhesins.
Therefore, CFA
MEFA-II carried antigenic elements of 8 adhesins of enterotoxigenic
Escherichia coli (ETEC),
and is expected to induce antibodies against all these 8 ETEC adhesins (C57,
CS12, CS14,
CS17, CS19, C521, EtpA and EaeH).
44
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
The structure of CFA MEFA-II of Example 3 is shown in Figure 6.
CFA MEFA-II amino acid sequence (SEQ ID No. 67))
MSLLEVIIVLGIIGTIAAGVVILAQRAFDSRAVTDLEAAPPEAGNYTVRVAMKDAYQRD
GKYPDFVDPLSLTANTIKTDTSGIPAAQLVQLGKADTQGTAPEAGNYISGDFIAIGGAVE
GEKSPRRGVKKGFAIELNGLTSGTAPS AGKYQEQCRSILGQVGAGSPVTRSDTTSWEYV
AGSNGQANNNDASQVDMSVAASTTVLRSLGNKKSPDIEDYQERTADKILSTCTAQVNSI
TLGSR
C57 Epitope: AGSPVTRSDTTS (SEQ ID No. 68)
C512 Epitope: GSNGQANNNDASQ (SEQ ID No. 69)
C514 Epitope: TSGTAPSAGKYQ (SEQ ID No. 70)
C517 Epitope: ADTQGTAPEAGNY (SEQ ID No. 71)
C519 Epitope: EAAPPEAGNY (SEQ ID No. 72)
EtpA Epitope: VEGEKSPRRGV (SEQ ID No. 40)
EaeH Epitope: KKSPDIEDYQER (SEQ ID No. 73)
CFA MEFA -II DNA sequence (SEQ ID No. 74)
ATGAGCCTGCTGGAAGTTATCATTGTTCTTGGCATTATCGGTACGATTGCAGCCGGT
GTCGTGATTCTGGCTCAGCGTGCGTTTGATTCACGTGCTGTGACTGATTTAGAAGCT
GCTCCGCCTGAGGCAGGTAATTACACAGTCCGCGTAGCAATGAAAGATGCTTATCA
ACGTGATGGTAAATATCCAGATTTTGTGGACCCATTAAGCCTTACTGCAAATACAAT
TAAAACTGATACAAGCGGAATACCTGCAGCACAGTTAGTTCAGCTTGGGAAAGCAG
ACACACAAGGAACTGCGCCTGAGGCAGGCAATTAC(CS17Epitope)ATTTCTGGCGACT
TTATCGCTATTGGCGGTGCTGTGGAGGGCGAAAAGTCCCCCCGTCGTGGCGTGAAAA
AAGGTTTTGCTATCGAACTTAATGGATTAACATCCGGAACTGCACCAAGTGCAGGTA
AGTATCAAGAGCAGTGCCGTTCTATTCTTGGGCAAGTTGGGGCTGGATCGCCGGTTA
CACGTAGTGATACGACATCTTGGGAATATGTTGCTGGTAGTAACGGCCAAGCGAAT
AACAATGATGCAAGCCAGGTAGATATGTCTGTGGCCGCCTCTACAACTGTTTTACGC
TCTTTAGGTAACAAAAAATCGCCGGATATTGAGGATTATCAGGAACGCACTGCAGA
CAAAATTCTAAGTACCTGTACTGCTCAGGTAAACTCAATTACTTTAGGTAGCCGTTA
A
CS7 major subunit (CsvA) (SEQ ID No. 75)
Amino Acid sequence:
MKKKLLIASVLAMATVSGSVLAAVTNGQLTFNWQGVVPSAPVTKNTWAFVNGLDIPFT
PGTEQLNITLGADKGITARSVKPYDFFIVPVTGTVTAGSPVTRSDTTSMNSVKAFLSSEPV
SNGFVGNKQLTLSTTAEAVTGQVAITLNGQPLKVGS ANATTVAMDTNKKESHISIDMN
AKASASDVAEGSAINFVAPVTFAVDI
Epitope:95-106 (12aa)
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
Nucleotide sequence: (SEQ ID No. 76)
ATGAAGAAAAAATTACTGATAGCTTCAGTATTAGCAATGGCAACCGTATCAGGTT
CTGTTTTGGCTGCTGTTACAAATGGCCAGCTCACATTTAATTGGCAGGGAGTGGTTC
CTTCTGCTCCCGTTACTAAAAATACGTGGGCTTTTGTGAACGGATTGGATATACCGTT
TACTCCTGGTACTGAACAGTTGAATATCACCCTTGGTGCAGATAAAGGTATCACAGC
CCGTTCGGTTAAGCCTTATGATTTTTTCATTGTTCCAGTTACTGGAACAGTAACTGCT
GGATCGCCGGTTACACGTAGTGATACGACATCTATGAATAGTGTGAAAGCTTTTCTA
TCAAGTGAACCCGTTTCTAATGGTTTTGTTGGCAACAAGCAGTTAACCCTGAGCACC
ACAGCAGAAGCAGTTACGGGGCAAGTCGCAATCACTTTAAATGGTCAGCCGCTTAA
AGTGGGGAGTGCTAATGCAACAACTGTTGCTATGGATACCAATAAAAAAGAGTCTC
ATATTTCTATTGATATGAATGCCAAGGCAAGTGCTTCGGATGTGGCGGAGGGTTCA
GCTATTAACTTTGTAGCTCCGGTAACATTTGCTGTTGATATTTAA
Primers to amplify the gene segment as antibody titration ELISA coating
antigen:
CS7-CsvA-F: CGC CAT GGA AAT GGC AAC CGT ATC AG (NcoI) (SEQ ID No. 77)
C57-CsvA-R: TCG GCC GCT TTA CGC CAC ATC CGA AGC ACT T (EagI) (SEQ ID. No
78)
C512 major subunit (CswA) (SEQ ID No. 79)
Amino acid sequence
MRKITSLIMAVTLMNSS AFAAIGSNGQANNNDAS QAELHFTGKLTSSLCQVATSDVKKE
IDLGELSKAALIASGRGPS QS FS VSLVNCDPTINTIS YALQDKNGS VGNYLVNQS GDTMA
KGVGVYIENNLNSPLKVDGSLNTVGVQKDGATALPDQVIPLTAYIGSTTPGAVADFATV
TPGLVDANAVMTIRAS AP
Epitope:23-35 (13aa)
Nucleotide sequence (SEQ ID No. 80)
ATGAGAAAAATTACGTCTCTGATCATGGCTGTTACTCTAATGAATAGCTCAGCCTT
CGCTGCGATCGGTAGTAACGGCCAAGCGAATAACAATGATGCAAGCCAGGCTGAAT
TGCATTTCACTGGTAAGTTGACTTCCAGTCTATGCCAGGTTGCTACATCAGATGTTAA
AAAAGAAATTGATCTAGGGGAACTTAGCAAAGCTGCGTTAATTGCATCAGGTCGAG
GGCCATCGCAGTCTTTTTCAGTTAGTTTGGTAAACTGTGACCCCACAATAAATACAA
TTAGTTATGCTTTGCAGGATAAAAACGGCAGTGTAGGTAATTATCTTGTAAACCAGT
CAGGTGACACGATGGCTAAGGGGGTTGGTGTCTATATTGAAAATAATTTAAATAGCC
CTTTGAAGGTTGATGGTTCACTTAATACTGTTGGTGTTCAGAAAGATGGTGCTACG
GCTTTACCTGATCAGGTTATTCCGTTGACTGCTTATATTGGTAGCACAACTCCGGGA
GCTGTGGCCGATTTTGCTACAGTAACTCCTGGCTTAGTTGATGCAAATGCAGTAATG
ACTATTCGTGCGAGCGCACCATAA
Primers to amplify the subunit segment as antibody titration ELISA coating
antigen:
46
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CA12-CswA-F: CATGCCATGGAAATGGCTGTTACTCTAATGAATAGCTCA (NcoI) (SEQ
ID No. 81)
CA12-CswA-R: GAGTCGGCCGCTTTATGAACACCAACAGTATTAAGTGAA (EagI) (SEQ
ID No. 82)
CS14 major subunit (CsuA) (SEQ ID No. 83)
Amino acid sequence
MKLKKTIGAMALSTIFVAVS AS AVEKNITVTASVDPTIDILQANGS ALPTAVDLTYLPGA
KTFENYSVLTQIYTNDPSKGLDVRLVDTPKLTNILQPTSTIPLTVSWAGKTLSTSAQKIAV
GDLGFGSTGTAGVSNS KELVIGATTSGTAPSAGKYQGVVSIVMTQSTDTAAPVP
Epitope:146-157 (12aa)
Nucleotide sequence (SEQ ID No. 84)
ATGAAATTAAAAAAAACTATTGGCGCAATGGCTCTGAGCACAATATTTGTAGCGG
TGAGTGCTTCAGCAGTAGAGAAAAATATTACTGTGACAGCCAGTGTTGATCCTACTA
TTGATATTCTTCAAGCAAATGGTTCTGCGCTACCGACAGCTGTAGATTTAACTTATCT
ACCTGGTGCAAAAACTTTTGAAAATTACAGTGTTCTAACCCAGATTTACACAAATGA
CCCTTCAAAAGGTTTAGATGTTCGACTGGTTGATACACCGAAACTTACAAATATTTT
GCAACCGACATCTACCATTCCTCTTACTGTCTCATGGGCAGGGAGGACATTAAGTAC
AAGTGCTCAGAAGATCGCAGTTGGCGATCTGGGTTTTGGTTCCACCGGAACGGCAG
GTGTTTCGAATAGTAAAGAATTAGTAATTGGAGCAACTACATCCGGAACTGCACCA
AGTGCAGGTAAGTATCAAGGCGTCGTTTCCATTGTAATGACTCAATCGACAAACT
AA
Primer to amplify the subunit the segment as antibody titration ELISA coating
antigen:
CA14-CsuA-F: CATGCCATGGAA ATGGCTCTGAGCACAATATTTGTAG (NcoI) (SEA
ID No. 85)
CA14-CsuA-R: GAGTCGGCCGCTTTAGTTTGTCGATTGAGTCATTACAATGGA (EagI)
(SEQ ID No. 86)
C517 major subunit gene (CsbA) (SEQ ID No. 87)
Amino acid sequence
MKLKKTIGAMAMATLFATMAAS AVEKNITVRASVDPKLDLLQADGTSLPDSIALTYSS
ASNNFEVYSLNTAIHTNDKS KGVVVKLS ASPVLSNIMKPNSQIPMKVTLGGKTLNTTDT
EFTVDTLNFGTSGVENVSSTQQLTIHADTQGTAPEAGNYQGIISLIMTQKT
Epitope:144-156 (13aa)
Nucleotide sequence (SEQ ID No. 88)
ATGAAACTGAAGAAAACAATTGGCGCAATGGCTATGGCGACTCTGTTTGCCACCA
TGGCTGCCTCTGCAGTCGAAAAAAATATTACTGTGAGGGCAAGTGTTGACCCTAAAC
TTGATCTTCTGCAAGCAGATGGAACTTCACTGCCGGACTCTATCGCATTAACCTATTC
47
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
TTCGGCTTCAAATAATTTTGAAGTTTACTCTCTTAATACTGCTATTCATACAAATGAC
AAAAGCAAGGGAGTTGTAGTGAAGCTGTCAGCTTCACCAGTTCTGTCCAATATTATG
AAGCCAAACTCGCAAATTCCGATGAAAGTGACTTTGGGGGGGAAGACGCTGAATAC
AACTGATACTGAGTTTACTGTTGATACTCTGAACTTTGGTACATCTGGTGTTGAAAA
CGTTTCTTCCACTCAACAGCTTACGATTCATGCAGACACACAAGGAACTGCGCCTGA
GGCAGGCAATTACCAAGGTATTATTTCTCTTATCATGACTCAAAAAACTTAA
Primers to amplify the segment as antibody titration ELISA coating antigen:
CA17-CsbA-F: CTAGCTAGCTAGATGGCTATGGCGACTCTGTTTGCCA (Nhe I) (SEQ ID
No. 89)
CA17-CsbA-R: GAGTCGGCCGCTTTATAATACCTTGGTAATTGCCTGCCTCA (EagI)
(SEQ ID No. 90)
CS19 major subunit (CsdA) (SEQ ID No. 91)
Amino acid sequence:
MKLKKTIGAMAMATLFATMAAS AVE KNITVRAS VDPKLDLLQADGTS LPDS IALTYS S
AS NNFEVYS LNT AIHTNDKT KAVVVKLS APAVLSNIMKPSSQIPMKVTLGGKTLSTADA
EFAADTLNFGASGVENVSSVQQLTIHAEAAPPEAGNYQGVISLIMTQKT
Epitope:145-154 (10aa)
Nucleotide sequence (SEQ ID No. 92)
ATGAAACTGAAGAAAACAATTGGCGCAATGGCTATGGCGACTCTGTTTGCCACCA
TGGCTGCCTCTGCAGTCGAAAAAAATATTACTGTGAGGGCAAGTGTTGACCCTAAAC
TTGATCTTCTGCAAGCAGATGGAACTTCACTGCCGGACTCTATCGCATTAACCTATTC
TTCGGCTTCAAATAATTTTGAAGTTTACTCTCTTAATACTGCTATTCATACAAATGAC
AAAACCAAGGCAGTTGTAGTGAAGCTGTCAGCTCCAGCAGTTCTGTCCAATATTATG
AAGCCAAGCTCGCAAATTCCGATGAAAGTGACTTTGGGGGGGAAGACGCTGAGTAC
AGCTGATGCTGAGTTTGCTGCTGATACTCTGAACTTTGGTGCATCTGGTGTTGAAAA
CGTTTCTTCCGTTCAACAGCTTACGATTCATGCAGAAGCTGCTCCGCCTGAGGCAGG
TAATTACCAAGGTGTTATTTCTCTTATCATGACTCAAAAAACTTAA
Primers to amplify the subunit segment as antibody titration ELISA coating
antigen:
CA19-CsdA-F: CTAGCTAGCTAGATGGCTATGGCGACTCTGTTTGCCA (Nhe I) (SEQ ID
No. 93)
CA19-CsdA-R: GAGTCGGCCGCTTTAGAGTCATGATAAGAGAAATAACAC (EagI) (SEQ
ID No. 94)
C521 major subunit (LngA) (SEQ ID No. 95)
Amino acid sequence
48
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
MSLLEVIIVLGIIGTIAAGVVILAQRAFDSRAVTDLVTNTNTVRVAMKDAYQRDGKYPD
FVDPLSLTANTIKTDTSGIPAAQLVQLGKITPDEVRNNISGDFIAIGGALTSNGAQVKKGF
AIELNGLSQEQCRSILGQVGNNWEYVAIGTS ASGSYAMTATGVDMSVAASTTVLRSLG
NGGQTTLTADKILSTCTAQVNSITLGSR
Epitope:49-60 (12aa) 69-81 (13aa)
Nucleotide sequence (SEQ ID No. 96)
ATGAGCCTGCTGGAAGTTATCATTGTTCTTGGCATTATCGGTACGATTGCAGCCG
GTGTCGTGATTCTGGCTCAGCGTGCGTTTGATTCACGTGCTGTGACTGATTTAGTAAC
TAATACAAATACAGTCCGCGTAGCAATGAAAGATGCTTATCAACGTGATGGTAAAT
ATCCAGATTTTGTGGACCCATTAAGCCTTACTGCAAATACAATTAAAACTGATACAA
GCGGAATACCTGCAGCACAGTTAGTTCAGCTTGGGAAAATTACACCAGACGAAGTG
CGTAATAACATTTCTGGCGACTTTATCGCTATTGGCGGTGCTTTAACTTCGAATGGTG
CTCAAGTTAAAAAAGGTTTTGCTATCGAACTTAATGGATTAAGCCAAGAGCAGTGCC
GTTCTATTCTTGGGCAAGTTGGGAATAACTGGGAATATGTTGCTATTGGTACTTCTGC
GTCTGGTTCATATGCCATGACAGCAACTGGTGTAGATATGTCTGTGGCCGCCTCTAC
AACTGTTTTACGCTCTTTAGGTAACGGTGGACAAACAACCTTGACTGCAGACAAAAT
TCTAAGTACCTGTACTGCTCAGGTAAACTCAATTACTTTAGGTAGCCGTTAA
Primers to amplify LngA gene the segment as antibody titration ELISA coating
antigen:
CA21-LngA-F: CATGCCATGGGCATGAGCCTGCTGGAAGTTATCATTGTT (NcoI) (SEQ
ID No. 97)
CA21-LngA-R: GAGTCGGCCGCTTTAACGGCTACCTAAAGTAATTGAG (EagI) (SEQ ID
No. 98)
EtpA adhesive subunit
Amino acid sequence (SEQ ID No. 99)
VSEITTGVGNAKATGSVEGEKSPRRGVRAMALSLLSGMMIMAHPAMS ANLPTGGQIVA
GSGSIQTPSGNQMNIHQNSQNMVANWNSFDIGKGNTVQFDQPSSSAVALNRVVGGGES
QIMGNLKANGQVFLVNPNGVLFGEGASVSTSGFVASTRDIKNDDFMNRRYTFSGGQKA
GAAIVNQGELTTNAGGYIVLAADRVSNSGTIRTPGGKTVLAA
Epitope:17-27 (11aa)
Nucleotide sequence (SEQ ID No. 100)
ATGAACCGTATATATAAACTGAAGTTTGACAAACGCCGCAACGAACTGGTGGTGG
TGAGTGAAATCACCACCGGCGTGGGTAATGCAAAAGCCACGGGCAGCGTGGAGGGC
GAAAAGTCCCCCCGTCGTGGCGTGCGCGCCATGGCGCTGAGCCTGCTGTCGGGTATG
ATGATAATGGCCCATCCGGCGATGTCAGCAAACCTGCCGACCGGTGGCCAGATTGT
GGCAGGTTCAGGCAGTATCCAGACGCCTTCCGGCAACCAGATGAATATTCATCAGA
ACAGCCAGAACATGGTGGCCAACTGGAACAGCTTTGACATTGGTAAAGGAAATACG
GTGCAGTTTGACCAGCCCAGCAGCAGTGCGGTGGCGCTGAACCGTGTTGTGGGTGG
49
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CGGTGAATCGCAGATTATGGGTAACCTGAAGGCGAATGGTCAGGTGTTCCTGGTTAA
CCCGAACGGCGTGCTGTTTGGTGAGGGGGCCAGTGTCAGCACGTCAGGTTTTGTGGC
ATCGACCCGCGACATTAAAAACGACGACTTCATGAACCGTCGTTACACCTTCAGCGG
CGGACAGAAAGCCGGGGCAGCGATTGTGAACCAGGGGGAACTGACCACAAATGCC
GGTGGCTATATTGTGCTGGCAGCAGACAGGGTCAGCAACAGTGGCACCATCCGTAC
GCCGGGCGGCAAGACCGTCCTGGCGGCCAGCGAGCGCATCACGCTGCAGCTGGATA
ATGGTGGCCTGATGTCCGTGCAGGTGACAGGAGATGTGGTTAATGCCCTGGTGGAA
AACCGCGGTCTGGTCAGTGCCCGGGATGGTCAGGTGTACCTGACCGCACTTGGCCG
GGGTATGCTGATGAACACGGTACTGAACGTGAGCGGGGTGGTGGAAGCCAGCGGTA
TGCACCGTCAGGACGGTAACATTGTACTGGACGGTGGCGACAGTGGTGTGGTGCAC
CTGAGTGGTACCCTGCAGGCGGACAATGCGTCCGGTCAGGGTGGTAAGGTTGTCGT
GCAGGGTAAGAATATTCTGCTGGACAAGGGCAGCAACATCACAGCAACCGGTGGTC
AGGGCGGCGGTGAAGTGTATGTCGGTGGCGGCTGGCAGGGTAAGGACAGCAACATC
CGTAATGCGGACAAGGTGGTGATGCAGGGCGGCGCCCGCATTGACGTTTCTGCAAC
GCAGCAGGGTAACGGCGGTACGGCTGTGCTGTGGTCAGACAGCTACACCAACTTCC
ATGGTCAGATTAGCGCGAAGGGCGGTGAGACCGGCGGTAACGGTGGTCGGGTGGA
GACCTCTTCGCACGGTAACCTGCAGGCATTTGGTACGGTCAGTGCATCCGCGAAGAA
AGGCAAGGCGGGTAACTGGCTGCTGGACTCGGCGGATATCACCATTGTGAATGGTA
GCAATGTTAGCAAAACTGAGACGACTCAATCGCCGCCGCACACGCAATTTGCACCC
ACCGCTGCGGGCTCTGCGGTCAGCAATACCAGTATCAACAACAGGCTGAACAACGG
GACCAGTGTCACTATTCTGACCCATCGCACAAGAACAGGCACAGCTCAGGGCGGGA
ATATTACCGTTAATGCGGCAATTAACAAAAGCAACGGAAGTGATGTCAACCTGACG
CTGCAGGCTGGCGGCAACATCACGGTAAACAACAGCATCACGTCCACCGAGGGTAA
GCTGAATGTTAATCTGTCGGGCGCCAGGACCAGCAATGGCAGTATCACCATTAGCA
ATAACGCCAATATAACGACCAATGGTGGGGATATAACTGTTGGGACGACAAATACT
TCAAACCGTGTGAATATATCTATTAATAACACTACCCTGAATGCGTCAAATGGCAAC
ATCCAGTTGACCGGGACCGGGACCGATAGCGGGATTCTGTTTGCTGGCAACAACAG
GCTGACGGCCAGTAACATTGCTCTTACCGGGAACAGTACGAGTGGGAATGCCATCA
ACCTTACAGGCACTGCCACGCTGAATGCCACGAATAACATTACTCTTACCGGGAGCA
GTACGAGTGGGAATGCCATCAACCTTAAAGGCAACAACACGCTGACGGCCAGTAAC
ATTACTCTTACCGGGGAAAGTACGAGTGGGAATGCCATCAACCTTACAGACACTAC
AGGCACTACCACGCTGAATGCCACGAATAACATCACTATGCAGGGGACCCGTGTTC
AGATTAAACACTCCAACATCACCGCGGGCAACTTTGCGCTGAATGCGACAGTGGCC
GGCTCTGAAATCAGCAATACCACGCTGACGGCCACCAACAACATCAACCTGGCGGC
TAAGACGAACAGTGCGAGCTCTGGTGTTTACCTGAAAGATGCAAGAATTACATCCA
CCAATGGCAGTATCACGGCTAACGGTACTGCCACAGCAAACGGCAAGGCCACGCAT
CTGGACGGCAACGTCACCCTGAATGCGTCAAATGGCAGAATCAAGTTGACCGGGAA
CGGGCACGGTAGCGCCTCCGGGATTCTGTTTGCTGGCAACAACAGGCTGACGGCCA
GTAACATTGCTCTTACCGGGAACAGTACGAGTGGGAATGCCATCAACCTTACAGGC
ACTGCCACGCTGAATGCCACGAATGACATTACTCTTACCGGGAGCAGTACGAGTGG
GAATGCCATCAACCTTACAGGCACTGCCACGCTGAATGCCACGAATAACATTACTCT
TACCGGGAGCAGTACGAGTGGGAATGC
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
CATCAACCTTAAAGGCAACAACACGCTGACGGCCAGTAACATTACTCTTACCGGGG
AAAGTACGAGTGGGAATGCCATCAACCTTACAGACACTACAGGCACTACCACGCTG
AATGCCACGAATAACATCACTATGCAGGGGACCCGTGTTCAGATTAAACACTCCAA
CATCACCGCGGGCAACTTTGCGCTGAATGCGACAGTGGCCGGCTCTGAAATCAGCA
ATACCACGCTGACGGCCACCAACAACATCAACCTGGCGGCTAAGACGAACAGTGCG
AGCTCTGGTGTTTACCTGAAAGATGCAAGAATTACATCCACCAATGGCAGTATCACG
GCTAACGGTACTGCCACAGCAAACGGCAAGGCCACGCATCTGGACGGCAACGTCAC
CCTGAATGCGTCAAATGGCAGAATCAAGTTGACCGGGAACGGGCACGGTAGCGCCT
CCGGGATTCTGTTTGCTGGCAACAACAGGCTGACGGCCAGTAACATTGCTCTTACCG
GGAACAGTACGAGTGGGAATGCCATCAACCTTACAGGCACTGCCACGCTGAATG
CCACGAATGACATTACTCTTACCGGGAGCAGTACGAGTGGGAATGCCATCAACCTTA
CAGGCACTGCCACGCTGAATGCCACGAATAACATTACTCTTACCGGGAGCAGTACG
AGTGGGAATGCCATCAACCTTAAAGGCAACAACACGCTGACGGCCAGTAACATTAC
TCTTACCGGGGAAAGTACGAGTGGGAATGCCATCAACCTTACAGACACTACAGGCA
CTACCACGCTGAATGCCACGAATAACATCACTATGCAGGGGACCCGTGTTCAGATTA
AACACTCCAACATCACCGCGGGCAACTTTGCGCTGAATGCGACAGTGGCCGGCTCT
GAAATCAGCAATACCACGCTGACGGCCACCAACAACATCAACCTGGCGGCTAAGAC
GAACAGTGCGAGCTCTGGTGTTTACCTGAAAGATGCAAGAATTACATCCACCAATG
GCAGTATCACGGCTAACGGTACTGCCACAGCAAACGGCAAGGCCACGCATCTGGAC
GGCAACGTCACCCTGAATGCGTCAAATGGCAGAATCAAGTTGACCGGGAACGGG
CACGGTAGCGCCTCCGGGATTCTGTTTGCTGGCAACAACAGGCTGACGGCCAGTAA
CATTGCTCTTACCGGGAACAGTACGAGTGGGAATGCCATCAACCTTACAGGCACTGC
CACGCTGAATGCCACGAATGACATTACTCTTACCGGGAGCAGTACGAGTGGGAATG
CCATCAACCTTACAGGCACTGCCACGCTGAATGCCACGAATAACATTACTCTTACCG
GGAGCAGTACGAGTGGGAATGCCATCAACCTTAAAGGCAACAACACGCTGACGGCC
AGTAACATTACTCTTACCGGGGAAAGTACGAGTGGGAATGCCATCAACCTTACAGA
CACTACAGGCACTACCACGCTGAATGCCACGAATAACATCACTATGCAGGGGACCC
GTGTTCAGATTAAACACTCCAACATCACCGCGGGCAACTTTGCGCTGAATGCGACAG
TGGCCGGCTCTGAAATCAGCAATACCACGCTGACGGCCACCAACAACATCAACCTG
GCGGCTAAGACGAACAGTGCGAGCTCTGGTGTTTACCTGAAAGATGCAAGAATTAC
ATCCACTAATGGCAGTATCACGACTAACGGTACTGCCACAGCAAACGGCAAGGCCA
CGCATCTGGACGGCAACGTCACCCTGAATGCGTCAAATGGCAGAATCAAGTTGACC
GGGAACGGGCACGGTAGCGCCTCCGGGATTCTGTTTGCTGGCAACAACAGGCTGAC
GGCCAGTAACATTGCTCTTACCGGGAACAGTACGAGTGGGAATGCCATCAACCTTAC
AGGCACTGCCACGCTGAATGCCACGAATGACATTACTCTTACCGGGAGCAGTACGA
GTGGGAATGCCATCAACCTTACAGGCACTGCCACGCTGAATGCCACGAATAACATT
ACTCTTACCGGGAGCAGTACGAGTGGGAATGCCATCAACCTTAAAGGCAACAACAC
GCTGACGGCCAGTAACATTACTCTTACCGGGGAAAGTACGAGTGGGAATGCCATCA
ACCTTACAGACACTACAGGCACTACCAC
GCTGAATGCCACGAATAACATCACTATGCAGGGGACCCGTGTTCAGATTAAACACTC
CAACATCACCGCGGGCAACTTTGCGCTGAATGCGACAGTGGCCGGCTCTGAAATCA
GCAATACCACGCTGACGGCCACCAACAACATCAACCTGGCGGCTAAGACGAACAGT
51
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
GCGAGCTCTGGTGTTTACCTGAAAGATGCAAGAATTACATCCACCAATGGCAGTATC
ACGGCTAACGGTACTGCCCCAGCAAACGACAATGCCACGTATCTGGACGGCAACGT
CACCCTGAATGCGTCAAATGGCAGCATCAAGTTGACCGGGAACGGGAACGGTAGCA
CCTCCGGGATTCTGTTTGCTGGCAACAACACGCTGACGGCCAGTAACATTACTCTTA
CCGGGAACAGTGAGGTGTACTGGCAATAG
Primers to amplify the segment as antibody titration ELISA coating antigen:
EtpA-F: CTAGCTAGCTAGATGAACCGTATATATAAACTG (NheI) (SEQ ID No. 101)
EtpA-R: GAGTCGGCCGCTTTATAATCTGACCATGGAAGTTGGTGTA(Eag I) (SEQ ID
No. 102)
EaeH subunit
Amino acid sequence: (SEQ ID No. 103)
MSHYKTGHKQPRFRYSVLARCVAWANISVQVLFPLAVTFTPVMAARAQHAVQPRLSM
GNTTVTADNNVEKNVASFAANAGTFLSSQPDSDATRNFITGMATAKANQEIQEWLGKY
GTARVKLNVDKDFSLKDSSLEMLYPIYDTPTNMLFTQGAIHRTDDRTQSNIGFGWRHFS
GNDWMAGVNTFIDHDLS RS HTRIGVGAEYWRDYLKLS ANGYIRASGWKKSPDIEDYQE
RPANGWDIRAEGYLPAWPQLGAS LMYEQYYGDEVGLFGKD KRQKDPHAIS AEVTYTP
V
Epitope:222-233 (12aa)
Nucleotide sequence (SEQ ID No. 104)
ATGTCACATTATAAAACAGGTCATAAACAACCACGATTTCGTTATTCAGTTCTGGCCCG
CTGCGTGGCGTGGGCAAATATCTCTGTTCAGGTTCTTTTTCCACTCGCTGTCACCTTTA
CCCCAGTAATGGCGGCACGTGCGCAGCATGCGGTTCAGCCACGGTTGAGCATGGGA
AATACTACGGTAACTGCTGATAATAACGTGGAGAAAAATGTCGCGTCGTTTGCCGCA
AATGCCGGGACATTTTTAAGCAGTCAGCCAGATAGCGATGCGACACGTAACTTTATTA
CCGGAATGGCCACAGCTAAAGCTAACCAGGAAATACAGGAGTGGCTCGGGAAATATG
GTACTGCGCGCGTCAAACTGAATGTCGATAAAGATTTCTCGCTGAAGGATTCTTCGCT
GGAAATGCTTTATCCGATTTATGATACGCCGACAAATATGTTGTTCACTCAGGGGGCAA
TACATCGTACAGACGATCGTACTCAGTCAAATATTGGTTTTGGCTGGCGTCATTTTTCA
GGAAATGACTGGATGGCGGGGGTGAATACTTTTATCGATCATGATTTATCCCGTAGTCA
TACCCGCATTGGTGTTGGTGCGGAATACTGGCGCGATTATCTGAAACTGAGCGCCAAT
GGTTATATTCGGGCTTCTGGCTGGAAAAAATCGCCGGATATTGAGGATTATCAGGAA
CGCCCGGCGAATGGCTGGGATATTCGTGCTGAGGGCTATTTACCCGCCTGGCCGCAGC
TTGGCGCAAGCCTGATGTATGAACAGTATTATGGCGATGAAGTCGGGCTGTTTGGTAA
AGATAAGCGCCAGAAAGACCCGCATGCTATTTCTGCCGAGGTGACCTATACGCCAGT
GCCTCTTCTGACACTGAGCGCCGGGCATAAGCAGGGCAAGAGTGGTGAGAATGACA
CTCGCTTTGGCCTGGAAGTTAATTATCGGATTGGCGAACCTCTGGCGAAACAACTC
GATACAGACAGCATTCGCGAGCGTCGGGTACTGGCAGGCAGCCGCTATGACCTGGTT
GAGCGTAATAACAACATCGTTCTTGAGTACCGCAAATCTGAAGTGATCCGTATTGCTC
TGCCTGAACGTATTGAAGGTAAGGGTGGTCAGACACTTTCCCTGGGGCTTGTGGTCA
GCAAAGCAACTCACGGACTGAAAAATGTGCAGTGGGAAGCGCCGTCATTACTGGCT
52
CA 03017809 2018-09-13
WO 2017/161366 PCT/US2017/023183
GAGGGTGGCAAAATTACCGGTCAGGGTAGTCAGTGGCAAGTAACGCTCCCGGCTTAT
CGTCCAGGCAAAGACAATTATTATGCGATTTCTGCGGTTGCCTACGATAACAAAGGCA
ATGCCTCAAAACGCGTGCAGACAGAGGTGGTCATTACCGGAGCAGGTATGAGCGCCG
ATCGCACGGCGTTAACGCTTGACGGTCAGAGCCGTATTCAAATGCTTGCTAACGGTAA
TGAGCAAAGACCGCTGGTGCTGTCTCTGCGCGACGCCGAGGGGCAGCCAGTCACGG
GCATGAAAGATCAGATCAAGACTGAACTAGCCTTCAAACCGGCTGGAAATATTGTGA
CTCGTTCCCTGAAGGCCACTAAATCACAGGCAAAGCCAACACTGGGTGAGTTCACCG
AAACTGAAGCAGGGGTGTATCAGTCTGTCTTTACTACCGGAACGCAGTCAGGTGAGG
CAACGATTACTGTTAGCGTTGATGGCATGAGCAAAACCGTCACTGCAGAACTGCGGG
CCACGATGATGGATGTGGCAAACTCCACCCTGAGCGCTAACGAGCCGTCAGGTGATG
TGGTTGCTGATGGTCAGCAAGCCTATACGTTGACGTTGACTGCGGTGGACTCCGAGG
GTAATCCGGTGACGGGAGAAGCCAGCCGCTTGCGATTTGTTCCGCAAGACACTAATG
GTGTAACCGTTGGTGCCATTTCGGAAATAAAACCAGGCGTTTACAGCGCCACGGTTTC
TTCGACCCGTGCCGGAAACGTTGTTGTGCGTGCTTTCAGCGAGCAGTATCAGCTGGG
CACATTACAACAAACGCTGAAGTTTGTTGCCGGTCCGCTTGATGCAGCACATTCGTCC
ATCCCCCTGAATCCTGATAAACCGGTGGTTGGCGGTACAGTTACGGCAATCTGGACGG
CAAAAGATGCCTATGACAACCCTGTGACCAGCCTCACGCCGGAAGCGCCGTCATTAG
CGGGTGCCGCTGCTGTAGGTTCTACGGCATCTGGCTGGACAAATAATGGTGATGGGAC
GTGGACTGCGCAGATTACTCTCGGCTCTACGGCGGGTGAATTAGAAGTTATGCCGAA
GCTAAATGGACAGGATGCGGCAGCAAATGCGGCAAAAGTAACCGTGGTGGCTGATGC
GTTATCTTCAAACCAGTCGAAAGTCTCTGTCGCAGAAGATCACGTAAAAGCCGGCGA
AAGCACAACCGTGACGCTTATTGCAAAAGATGCACATGGCAACACTATCAGTGGTCT
TTCGTTGTCGGCAAGTTTGACGGGGACCGCCTCTGAAGGGGCGACCGTTTCCAGTTG
GACCGAAAAAGGTGACTGTTCCTATGTTGCTACGTTAACTACAGGCGGAAAGACGGG
CGAGCTTCGTGTCATGCCGCTCTTCAACGGCCAGCCAGCAGCCACCGAAGCCGCGCA
GTTGACGGTCATCGCCGGAGAGATGTCATCAGCGAACTCTACGCTTGTTGCGGACAAT
AAGGCTCCGACCGTCAAAATGACGACGGAACTCACCTTCACCGTGAAGGATGCGTAC
GGGAACCCGGTCACCGGGCTGAAGCCAGATGCACCAGTGTTTAGCGGTGCCGCCAG
CACGGGGAGTGAGCGTCCTTCAGCAGGAAACTGGACAGAGAAAGGTAATGGGGTCT
ACGTGGCGACCTTAACGCTGGGATCTGCCGCGGGTCAGTTGTCTGTGATGCCGCGAG
TGAACGGCCAAAATGCCGTTGCTCAGCCACTGGTGCTGAACGTTGCAGGTGACGCAT
CTAAGGCTGAGATTCGTGATATGACAGTGAAGGTTAATAACCAACTGGCTAATGGACA
GTCTGCTAACCAGATAACCCTGACCGTCGTGGACAGCTATGGTAACCCGTTGCAGGG
GCAAGAAGTTACGCTGACTTTACCGCAGGGTGTGACCAGCAAGACGGGGAATACAGT
AACAACCAATGCGGCAGGGAAAGTGGACATTGAGCTTATGTCAACGGTTGCGGGGG
AACACAGCATCACGGCCTCAGTGAATAATGCTCAGAAGACGGTTACGGTGAAATTCA
AGGCGGATTTCAGTACCGGTCAGGCGACCCTGGAGGTTGATGGCAGCACGCCAAAA
GTGGCAAACGACAATGATGCCTTTACGCTGACGGCAACGGTTAAGGATCAATACGGC
AACCTTCTGCCTGGCGCTGTGGTCGTCTTTAATCTGCCTCGGGGCGTCAAACCGCTTG
CAGACGGTAATATCATGGTGAACGCCGACAAGGAGGGTAAAGCGGAACTGAAAGTG
GTCTCCGTGACTGCCGGAACGTATGAGATCACGGCGTCGGCAGGAAATGACCAGCCT
TCGAATGCGCAGTCTGTAACGTTTGTGGCCGATAAGACTACGGCGACCATCTCCAGTA
TTGAGGTGATTGGCAACCGTGCAGTGGCGGATGGCAAAACCAAACAGACGTATAAA
GTTACGGTGACTGATGCCAATAACAACCTGTTGAAGGATAGCGACGTGACGCTGACT
GCCAGCTCGGAAAATTTAGTTCTGGATCCTAAAGGGACGGCGAAAACTAATGAGCAA
GGACAGGCTGTTTTCACCGGCTCTACCACTATCGCAGCGACATATACACTCACGGCGA
53
CA 03017809 2018-09-13
WO 2017/161366
PCT/US2017/023183
AAGTGGAACAGGCCAACGGTCAGGTATCGACGAAAACTGCTGAATCTAAATTCGTCG
CGGATGATAAAAACGCGGTGCTCGCCGCATCTCCAGAACGTGTAGATTCTCTGGTGG
CGGACGGGAAGACTACTGCAACAATGACGGTTACCCTGATGGCGGGAGTCAATCCCG
TAGGAGGAAGTATGTGGGTCGACATTGAGGCTCCGGAAGGAGTGACGGAGAAGGAT
TATCAATTCCTGCCGTCGAAGGCTGACCATTTCTCAGGTGGGAAAATCACGCGTACAT
TTAGTACCAGCAAGCCAGGTGTCTATACGTTCACATTCAACGCACTGACGTATGGCGG
GTACGAAATGACGCCTGTGAAGGTGACAATTAACGCCGTTGCTGCAGAGACTGAAAA
TGGCGAGGAGGAGATGCCATAA
Primers to amplify the segment as antibody titration ELISA coating antigen
EaeH-F: CATGCCATGGAAATGGGAAATACTACGGTAACTGC (NcoI) (SEQ ID No. 105)
EaeH-R: GAGTCGGCCGCATTAGGTTCGCCAATCCGATAATTAACTT(EagI) (SEQ ID No.
106)
Adult female mice, 10 per group, were subcutaneously (SC) immunized with 40
lug
recombinant CFA MEFA-II protein, with 2 lug dmLT adjuvant. Immunized mice
received two
boosters in an interval of two weeks. Two weeks after the final booster, mice
were anesthetized
and exsanguinated. A group of 10 mice without immunization were used as the
control. Mouse
serum samples were used for antibody titration and antibody adherence
inhibition assay.
Antibody titration ELISAs using recombinant subunit proteins as coating
antigens (400
ng per well) was performed. Serum samples from each mouse from the immunized
group were
detected great titers of anti-057, -CS12, -CS14, -CS17, -CS19, -0521, -EaeH
and anti-EtpA IgG
antibodies.
Results and Conclusions
All mice in the immunization group developed antibodies specific to C57, CS12,
CS14,
CS17, CS19, C521, EaeH and EtpA. No antigen-specific antibodies were detected
from serum
samples of the control mice. Moreover, serum samples from the mice SC
immunized with CFA
MEFA-II showed antibody neutralization activities. ETEC bacteria expressing
C57, CS12,
CS14, CS17, CS19, C521, EaeH, or EtpA adhesin, after incubated with the serum
samples of the
immunized mice, showed a significant reduction in adherence to Caco-2 cells,
compared the
bacteria incubated with the serum samples of the control mice. These results
are show in Figure
7, where the IgG antibody titers are illustrated for each mouse, where each
dot represented a IgG
titer from an individual mouse and the bars indicated mean titers.
Table 5. Mouse serum antibody in vitro adherence inhibition assay results.
Caco-2ce11s (5 x105)
were incubated with each ETEC bacteria strain expressing a different adhesion
(in PBS), ETEC
bacteria premixed with serum of the control mice, or ETEC bacteria premixed
with serum of the
mice immunized with CFA MEFA-II
E.coli strains PBS serum of control serum of
mice
immunized mice
H10407-EaeH/EtpA/CFA/I/LT/STa (x102) 136.8 5.6 130.8 4.4 44
2.7 p<0.001
JF2327, CS7/LT (x103) 77.2 3.1 75 3.0 30.8 2.3
p<0.001
54
CA 03017809 2018-09-13
WO 2017/161366
PCT/US2017/023183
JF2363, CS7/EatA/LT (x103) 105.6 5.1 100.8 4.3 33.2 1.9
p<0.001
3276, CS12/CS20/LT/STa (x103) 107 6.3 100 5.0 31.4 2.6
p<0.001
3309, CS12/CS20/CS21/LT/STa (x103) 145 9.4 140 7.1 37
2.9 p<0.001
E7476A, CS14 (x102) 131.8 3.1 127.4 7.7 63.8 3.2
p<0.001
JF2125, CS14/EtpA/LT (x102) 75.4 2.3 73.8 5.5 15.6 1.5
p<0.001
E20738A, CS17 (x102) 117.8 8.0 115 10.8 50.4 3.2
p<0.001
JF2350, CS17/EtpA/EatA/LT (x102) 219.8 9.2 208.4 9.6 133.2
5.0
p<0.001
D526-1, C519 (x102) 182.4 10.4 179.4 8.7 61
3.4 p<0.001
JF2101, C521/EtpA/EatA/5Ta (x102) 45.6 3.0 40.6 1.8 14.8 1.5
p<0.001
JF2318, EtpA/STa (x102) 91.8 5.8 87.2 4.5 33.4 3.5
p<0.001
JF1389, EtpA/C55/C56/LT/5Ta (x102) 43 2.3 41 4.4 18.2 2.6
p<0.001
